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Platelets contribute to the regulation of tissue neovascularization, although the specific
factors underlying this function are unknown. Here, we identified the complement anaphy-
latoxin C5a-mediated activation of C5a receptor 1 (C5aR1) on platelets as a negative reg-
ulatory mechanism of vessel formation. We showed that platelets expressing C5aR1 exert an
inhibitory effect on endothelial cell functions such as migration and 2D and 3D tube for-
mation. Growth factor- and hypoxia-driven vascularization was markedly increased in
C5ar1−/− mice. Platelet-specific deletion of C5aR1 resulted in a proangiogenic phenotype with
increased collateralization, capillarization and improved pericyte coverage. Mechanistically,
we found that C5a induced preferential release of CXC chemokine ligand 4 (CXCL4, PF4)
from platelets as an important antiangiogenic paracrine effector molecule. Interfering with the
C5aR1-CXCL4 axis reversed the antiangiogenic effect of platelets both in vitro and in vivo.
In conclusion, we identified a mechanism for the control of tissue neovascularization through
C5a/C5aR1 axis activation in platelets and subsequent induction of the antiangiogenic
factor CXCL4.
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T issue homeostasis and healing processes are of funda-mental importance in living organisms. The complementsystem, a central player of the innate immune response,
contributes to both tissue homeostasis and dysfunction1. Recent
clinical and preclinical trials have shown that the complement
system may be a promising therapeutic target for the restoration
of tissue functionality in different pathological conditions, such as
stroke2, asthma3, and myocardial infarction4,5.
The complement system comprises a group of >30 plasma and
cell-bound proteins that are activated canonically by one of the
three pathways or noncanonically through plasma or cell-bound
proteases6. The complement system exerts functions in innate
immune defense as an important sentinel system7. It is tightly
integrated and involved in crosstalk with other humoral and
cellular arms of innate immunity, such as the contact system,
pattern-recognition receptors, and immunoglobulin G (IgG) Fc
receptors. Functions of the complement system include the
opsonization of microbial intruders, the clearance of immune
complexes, and the induction and regulation of the inflammatory
response through the small cleavage fragments of C3 and C5,
known as anaphylatoxins8. Activation of the terminal pathway of
the cascade results in the assembly of C5b–C9, which can
nucleate the membrane attack complex and mediate the osmotic
lysis of target cells1. Previously, components of the complement
cascade have been demonstrated to regulate angiogenesis in dif-
ferent pathophysiological settings9–12, and the therapeutic value
of targeting complement receptors is currently being explored in
clinical trials13. Nevertheless, the exact mechanisms by which the
complement system may interfere with proangiogenic or anti-
angiogenic cells or receptors remain to be determined.
Platelets play a decisive role in diseases that are featured by
thrombus formation, and thus targeting platelet-associated func-
tions is an established therapeutic principle for treating these
diseases14,15. Beyond their classical function in blood hemostasis,
platelets contribute to inflammation16, immunomodulation17,18,
and atherosclerosis19. Increasing evidence points to a functional
intersection between hemostasis and activation of the complement
cascade20. Previous studies have reported that complement
receptors may be expressed on platelets21,22. We recently showed
that the complement C3a receptor expressed on platelets mod-
ulates platelet aggregation23,24. Interestingly, platelets store
proangiogenic and antiangiogenic factors in distinct granules and
can release them upon stimulation. For instance, platelet α-
granules contain proangiogenic vascular endothelial growth factor
(VEGF) and antiangiogenic CXC chemokine ligand 4 (CXCL4,
PF425–27). However, knowledge regarding the modulation of
angiogenesis by platelets in vivo and the specific factors orches-
trating this complex process is limited18,27.
Here we addressed the crosstalk between the complement system
and platelets in the context of ischemia-induced revascularization
in vivo and find that C5a receptor 1 (C5aR1) expressed on platelets
regulates the angiogenesis-related functions of platelets.
Results
Platelets express complement anaphylatoxin receptor C5aR1 in
an environment of ischemia-induced revascularization. While
it has been described that platelets contain proangiogenic and
antiangiogenic factors27, very little information exists regarding
their regulatory function of hypoxia-driven revascularization and
on how the release of these paracrine mediators is regulated. To
address the role of platelets in the context of vessel formation and
complement activation in vivo, we performed hindlimb ischemia
experiments28. In this model, femoral artery ligation causes
ischemia in the distal hindlimb tissue, which triggers
revascularization.
Interestingly, we were able to detect complement activation in
ischemic but not in nonischemic control hindlimb tissue, as
demonstrated by the deposition of C3b, which colocalized with
the formation of vascular structures (Fig. 1a). Further, we found
significantly increased expression of complement anaphylatoxin
receptor C5ar1 on the level of mRNA in ischemic hindlimb
muscle tissue as compared with the nonischemic contralateral
hindlimb (Fig. 1b). We also evaluated the presence of CD42b+
platelets within the muscle tissue and found a significant
increase in platelet abundance in the ischemic versus the
nonischemic control hindlimb (Fig. 1c and Supplementary
Fig. 1a, b). Accordingly, the platelet lineage-specific markers
Cd42b mRNA and Cd41 mRNA were significantly elevated in
the ischemic tissue (Fig. 1d). In vitro, we could demonstrate that
adenosine diphosphate (ADP)-induced adherence of platelets to
endothelial cells under static conditions was increased when the
endothelium was hypoxic (Fig. 1e). Consistently, analysis of
ischemic hindlimb muscles revealed colocalization of C5aR1
with the platelet marker CD42b at different stages of hindlimb
revascularization (Fig. 1f). Thus, platelets spatiotemporally
colocalize with complement activation and express C5aR1 in
angiogenic tissue.
C5a-mediated activation of C5aR1 on platelets inhibits endo-
thelial functions that are important for angiogenesis. As both
platelets and the complement system have been shown to regulate
angiogenesis12,29, we further questioned whether C5aR1 expres-
sed on platelets modulates endothelial functions that are impor-
tant for angiogenesis. We were able to detect C5aR1 in
unstimulated washed platelets (Fig. 2a, b), which was markedly
enhanced after collagen-related peptide (CRP) stimulation
(Fig. 2c), slightly upregulated after ADP stimulation (Fig. 2d) and
not altered after C5a stimulation (Fig. 2e).
Subsequently, we coincubated endothelial cells with platelets
isolated from wild-type (WT) or C5ar1−/− mice. There was no
difference in endothelial cell proliferation after the addition of
platelets in the presence or absence of C5aR1 using the murine
endothelial cell line MHEC-5T (Supplementary Fig. 2a, b).
However, endothelial migration was increased by coincubation
with C5ar1−/− platelets compared to coincubation with WT
platelets using primary mouse lung endothelial cells (MLECs;
Fig. 2f). The purity of primary cells was at least 90%, as verified by
staining for CD102, CD144, and CD31 (Supplementary Fig. 3).
Similarly, endothelial tube formation in an in vitro two-
dimensional and three-dimensional (3D) tube-formation assay
was increased after coincubation with C5ar1−/− platelets or
C5ar1−/− platelet supernatant compared to coincubation with
WT platelets or supernatant in MHEC-5T cells and in primary
MLECs (Fig. 2g–k). Next, we preincubated human platelets with
the C5aR1-specific antagonist PMX53 or control peptide before
their addition to human umbilical vein endothelial cells
(HUVECs) in the presence of C5a. The results show that
endothelial tube formation was significantly enhanced when
C5aR1 activity was inhibited by PMX53 (Fig. 2l). In order to
better characterize platelet–endothelial interactions in vitro, we
assessed whether WT or C5ar1−/− platelets differ with respect to
static adhesion to endothelial cells. ADP induced a significant
increase in adhesion but there was no difference between WT and
C5aR1-deficient platelets (Fig. 2m, n).
Increased ischemia-induced revascularization in C5aR1-
deficient mice. Next, we explored the functional role of C5aR1
in vessel formation in vivo by assessing murine embryonic
angiogenesis and hindlimb ischemia-induced revascularization.
Whole-mount staining was performed on E11.5 WT or C5ar1−/−
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embryonic hindbrains. No impact of C5aR1 on developmental
angiogenesis could be detected (Supplementary Fig. 4). In con-
trast, we observed an effect of C5aR1 deficiency on ischemia-
driven vessel growth. When we monitored revascularization after
femoral artery ligation by repeated laser Doppler imaging (LDI)
measurements over 14 days, we found significantly enhanced
perfusion in C5ar1−/− animals, indicating faster and more pro-
nounced revascularization when compared to WT control ani-
mals (Fig. 3a, b). Next, gastrocnemius muscles were explanted
from ischemic hindlimbs after 14 days, and vessel density was
quantified by immunofluorescence staining for isolectin B4 (IB4;
green) and 4,6-diamidino-2-phenylindole (DAPI; blue; Fig. 3c).
Vessel density of hindlimb muscles from C5ar1−/− mice was
significantly higher as compared with that of WT controls after
the induction of hindlimb ischemia (Fig. 3c, d). Subsequently, we
administered platelet-depleting serum to both WT and C5ar1−/−
mice after induction of hindlimb ischemia over 14 days. Platelet
depletion was effective and showed a platelet-depletion efficiency
>90% measured in peripheral blood of mice (Supplementary
Fig. 5) Upon platelet depletion, we observed no significant dif-
ference in revascularization between both strains any more,
suggesting a critical role of C5aR1 activation on platelets for
ischemia-induced angiogenesis (Fig. 3e). Accordingly, vessel
density was comparable in both the groups (Fig. 3f).
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The increased revascularization in C5aR1-deficient mice is
mediated by platelet C5aR1 stimulation-driven collateraliza-
tion as well as capillary and pericyte growth. To further
define the role of platelet C5aR1 in vivo, we crossed floxed GFP-
C5ar1fl/fl30 mice with Pf4-cre+ mice31 and generated Pf4-cre+
C5ar1fl/fl mice, lacking C5aR1 in platelets (Supplementary Fig. 6).
When we induced hindlimb ischemia and performed repeated
LDI measurements over 14 days in Pf4-cre+ C5ar1fl/fl mice, we
found stronger revascularization in platelet-specific C5ar1-
knockout mice than in Pf4-cre− C5ar1fl/fl littermate controls
(Fig. 4a, b). Similar to C5ar1−/− mice, we detected an increased
vessel density in the ischemic muscle tissue of Pf4-cre+ C5ar1fl/fl
mice (Fig. 4c, d). To rule out that a difference in platelet
deposition upon C5aR1 deficiency in ischemic tissues is respon-
sible for the observed effects, we assessed platelet abundance and
microthrombi size in whole-muscle sections of ischemic Pf4-cre+
C5ar1fl/fl mice and Pf4-cre− C5ar1fl/fl controls (Fig. 4e). We found
no significant differences between both the groups (Fig. 4f). As
CXCL4 (PF4) is also known to be expressed by monocytic cells,
which are important mediators of ischemia-induced
revascularization32, we next assessed whether Pf4-cre+ C5ar1fl/fl
mice showed altered C5aR1 expression on monocytes or mac-
rophages compared to Pf4-cre− C5ar1fl/fl mice but found no
differences (Supplementary Fig. 7).
To obtain insights into the mechanisms underlying the increased
revascularization observed in Pf4-cre+ C5ar1fl/fl mice in vivo, we
performed micro-computed tomographic (microCT) analysis of
platelet-specific C5ar1-knockout mice subjected to the hindlimb
ischemia model at day 9. After 3D reconstruction, the occluded vessel
could be identified by comparison with the contralateral control
hindlimb (Fig. 5a, b, arrows). Furthermore, collateral artery formation
could be observed (Fig. 5a, b and Supplementary Movies 1a–d). By
virtual reconstruction, the vascular tree was extracted from the images
and analyzed (Supplementary Fig. 8a, b). Vessel size distribution in
both the groups (Pf4-cre+ C5ar1fl/fl and Pf4-cre− C5ar1fl/fl) was
assessed. The analysis yielded an increase in small- and medium-sized
vessels, which comprise arterial collateral vessels, in the proximal
section of the hindlimb (Fig. 5c). We also considered the possibility
that platelet C5aR1 impacts on the formation of pre-existent collateral
vessels, which are known to be important for the initial phase of
ischemia-induced revascularization33. Therefore, the vascular tree in
nonischemic hindlimbs of both genotypes was quantified. No
difference in mean vessel size could be observed (Supplementary
Fig. 8c).
In the distal hindlimb, we stained for smooth muscle actin (SMA)
and NG2 expression, which denotes arterial vessels. We then
quantified the size of the largest arteries and arteriolar density within
the gastrocnemius muscle (Fig. 5d, e). However, no significant
differences could be detected between Pf4-cre+ C5ar1fl/fl mice and
Pf4-cre− C5ar1fl/fl mice in this distal muscle. NG2 staining allowed
us to determine pericyte abundance and pericyte coverage of vessels.
Comparing ischemic hindlimb muscles from platelet-specific
C5aR1-deficient mice with Pf4-cre− C5ar1fl/fl control mice at day
14 after induction of ischemia, we observed increased pericyte
density and enhanced pericyte coverage in platelet-specific C5aR1-
deficient mice (Fig. 5f, g). This effect may explain the amplified
vessel density in Pf4-cre+ C5ar1fl/fl mice (Fig. 4c, d).
Our observations that platelet C5aR1 inhibits endothelial cell
functions, which are relevant for angiogenesis in vitro, and our
findings that platelet-specific C5ar1−/− animals exhibit increased
ischemia-induced revascularization prompted us to investigate
the regulatory mechanisms underlying this process.
Platelet C5aR1 mediates the release of antiangiogenic, platelet-
derived CXCL4. To elucidate the mechanisms underlying platelet
C5aR1-mediated inhibition of vessel growth and endothelial
functions, we stimulated isolated platelets with C5a or vehicle
control. A membrane-based antibody array was performed using
the harvested supernatants to obtain insights into the regulation
of secreted antiangiogenic factors (Fig. 6a). Interestingly, the
platelet α-granule component CXCL4 was strongly induced after
C5a stimulation (Fig. 6b). Bonferroni’s post hoc analysis showed
significant differences compared to all factors except Angiopoie-
tin-1, for which C5a induced a downregulation, as well as
endostatin (Supplementary Fig. 9).
To further approach the mechanism of C5a-induced
CXCL4 secretion, we stained stimulated platelets for the α-
granule components P-selectin and CXCL4 (Fig. 6c). Low-dose
ADP and C5a stimulation induced platelet activation, as indicated
by P-selectin upregulation, and P-selectin mobilization toward
the cell periphery (ring-like staining pattern, arrows; Fig. 6c, d).
C5a induced an altered secretion response compared to ADP, as
indicated by a decrease in CXCL4 intensity relative to P-selectin
intensity after C5a stimulation compared with ADP (Fig. 6e).
Interestingly, using confocal microscopy (Supplementary
Fig. 10) we found α-granules, which contain predominantly
CXCL4 over P-selectin as well as granules containing both
CXCL4 and P-selectin (Fig. 6f, g). When we stimulated platelets
Fig. 1 Complement anaphylatoxin receptor C5aR1 associated with platelets is abundant in ischemic tissue. WT mice were subjected to hindlimb
ischemia as described in the “Methods” section. a One week after the induction of hindlimb ischemia, ischemic muscles revealed abundant complement
activation (left side), as demonstrated by the presence of the C3 cleavage product C3b (red). IB4 staining (green) depicts vascular structures; DAPI (blue)
depicts nuclei. The nonischemic contralateral control muscle only displayed minimal complement C3b deposition (right side). ×200 magnification, scale
bars represent 200 µm. Image is representative of at least four analyzed muscles. b Furthermore, ischemia resulted in significantly increased mRNA levels
of the anaphylatoxin receptor C5ar1 compared with nonischemic contralateral hindlimb muscles as internal controls. Data are the mean ± SEM (n= 4
independent experiments) and are shown as the percentage of control. mRNA levels in the contralateral control muscles of WT animals represent 100%.
*p < 0.05. c In the ischemic hindlimb tissue, more platelets could be detected compared to the nonischemic control limb using CD42b (red). Displayed is a
representative image, IB4 staining (green) depicts vascular structures; DAPI (blue) depicts nuclei. Scale bars represent 10 µm. Image is representative of
11–12 whole-muscle sections per group. d RT-PCR analysis detected significantly increased mRNA levels of the platelet marker Cd42b as well as the platelet
marker Cd41 compared with the contralateral unaffected muscles. Data are presented as the mean ± SEM (n= 4 independent experiments) and are shown
as the percentage of control. mRNA levels in the contralateral control muscles of WT animals represent 100%. *p < 0.05. e In a static adhesion assay of
platelets on endothelial cells (MHEC), the ADP-induced increase in adhesion was significantly greater under ischemic conditions with an ischemically
preconditioned endothelial monolayer compared to normoxic endothelial cells. Data are presented as the mean ± SEM (n= 4 independent experiments)
and are shown as the percentage of control. ADP-induced platelet adhesion to normoxic endothelial cells expressed as the area fraction of platelet-specific
staining represents 100%. *p < 0.05. f Immunofluorescent costaining of murine hindlimb muscle sections 4 as well as 14 days after the induction of
ischemia at ×630 magnification (left side) showing colocalization of the platelet markers CD42b (red) and C5aR1 (green). Representative images confirm
that the cells are anuclear (DAPI negative, blue). Control staining of muscles from C5ar1−/− mice (right side) verifies specificity of C5aR1 staining. Scale
bars represent 5 µm. Image is representative of at least four analyzed muscles. Two-sided Student’s t test in b, d, e.
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with C5a, we observed a release of these CXCL4-predominant
granules from platelets measured as the reduction in area fraction
(Fig. 6h) but not of granules containing both CXCL4 and P-
selectin or granules containing P-selectin but not CXCL4. These
findings strongly suggest that C5a induces the secretion of an α-
granule subset predominantly holding CXCL4.
Using human cells, conventional enzyme-linked immunosor-
bent assay (ELISA) measurements of the CXCL4 concentration in
the supernatant of C5a-stimulated platelets confirmed a dose-
dependent and significant increase compared with vehicle
control-treated platelets (Fig. 6i). Next, time and dose depen-
dency in murine platelets were assessed to find the optimal
stimulation conditions in murine platelets (Supplementary
Fig. 11). Maximum CXCL4 release was observed at a C5a
concentration of 200 ng/ml for mouse samples and 2000 ng/ml
for human cells (Fig. 6i and Supplementary Fig. 12a). A dose-
dependent CXCL4 secretion effect was achieved at stimulation
conditions of 10 min at 25 °C and 10 min at 37 °C
(Supplementary Fig. 12). Analyzing megakaryocytes from C5ar1
−/− mice, we observed no difference in CXCL4 granule area
fraction (Fig. 6j, k) compared to WT cells. Furthermore, there was
no difference in Cxcl4 mRNA between WT and C5ar1−/−
megakaryocytes as analyzed by real-time PCR (Fig. 6l), indicating
regulation of CXCL4 on the platelet rather than on the
megakaryocyte level.
In order to compare C5a-induced CXCL4 release with
CXCL4 secretion induced by classical platelet agonists, we
performed platelet stimulation with different platelet activators
and compared the secretion response of WT and C5ar1−/− mice
(Supplementary Fig. 13). We found that, while WT and C5ar1−/−
mice displayed no significant differences in response to classical
agonist-induced CXCL4 release, no significant CXCL4 secretion
occurred after C5a stimulation of C5ar1−/− platelets (Supple-
mentary Fig. 13b). In WT mice, CXCL4 level after 200 ng/ml C5a
stimulation was comparable to 25 μM ADP stimulation (Supple-
mentary Fig. 13a). WT and C5ar1−/− platelets did not differ
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significantly in their aggregation behavior (Supplementary
Fig. 14a, b). To further rule out that defects in hemostasis
account for the neovascularization phenotype of C5ar1−/− mice,
we carried out additional in vivo experiments using ferric
chloride-induced vascular injury. We observed no significant
difference in time to thrombus formation in the absence of C5aR1
in comparison to WT mice (Supplementary Fig. 14c). Further-
more, C5aR1 deficiency had no significant effect on in vivo
bleeding time (Supplementary Fig. 14d). Nevertheless, as the
results in Fig. 6c, d already showed, C5a induced platelet
activation. We quantified C5aR1-dependent platelet activation
using flow cytometry and found that there was significantly
increased but modest platelet activation in WT platelets following
C5a stimulation but not in C5ar1−/− platelets (Fig. 6m).
Furthermore, C5a induced a dose-dependent calcium signal
(Supplementary Fig. 14e). However, C5a had no effect on other
platelet activation markers like GPVI, CD40L, CD61, and
platelet–leukocyte aggregate formation (Supplementary Fig. 14f).
Finally, C5a had no impact on classical platelet functions such as
adhesion to von Willebrand factor or aggregation (Supplementary
Fig. 15). C5aR1 deficiency did not influence C3aR protein content
of platelets (Supplementary Fig. 16). C3aR has recently been
shown to modulate platelet aggregation24. Similarly, C3aR
receptor expression profile of platelets was not significantly
altered in the absence of C5aR1 (Supplementary Fig. 17).
Next, we assessed the impact of C5a on the secretion of other
angiogenic factors, which are known to be stored in platelets, by
conventional ELISA. Compared to other agonists and vehicle
control, C5a did not induce secretion of thrombospondin 1
(Supplementary Fig. 18a), endostatin (Supplementary Fig. 18b), or
platelet-derived growth factor (PDGF; Supplementary Fig. 18c)
from human platelets. Also, C5a stimulation had no effect on
the secretion of δ-granule cargo ATP from platelets (Supplementary
Fig. 19). The granule content of platelets fromWT versus C5ar1−/−
or Pf4-cre− C5ar1fl/fl versus Pf4-cre+ C5ar1fl/fl mice showed no
significant differences, respectively (Supplementary Fig. 20). Then
we analyzed the effect of C5 deficiency on C5aR1-dependent
CXCL4 secretion from platelets. Platelets isolated from C5-deficient
mice expressed C5aR1 (Supplementary Fig. 21a) but displayed C5a-
dependent CXCL4 secretion after stimulation with higher C5a
concentrations (500 ng/ml; Supplementary Fig. 21b), while no
major differences were detected in the activation response of C5−/−
platelets compared to WT platelets (Supplementary Fig. 21c, d).
C5aR2 is known to modulate C5aR1 function in a number of
different cell types34. However, we could not detect relevant C5aR2
expression on platelets or an effect of C5aR2-specific stimulation on
CXCL4 release from platelets (Supplementary Fig. 22).
Furthermore, we analyzed several potential pathways, which
could link binding of C5a via C5aR1 to CXCL4 secretion. We
tested phosphorylation of Akt, phosphoinositide-3 kinase (PI3K),
glycogen synthase kinase 3β (GSK-3β), p44/42 mitogen-activated
protein kinase (MAPK), PLCβ3, PLCγ2, protein kinase A (PKA),
and RAP1. Interestingly, we found that the signal is conducted via
the Gβγ subunit of C5aR1 and not by Gαi, as we found C5a-
dependent phosphorylation of PI3K and Akt but not PKA
(Fig. 6n–q and statistical analysis in Supplementary Fig. 23). PKC
activation seems to be central for C5a-induced CXCL4 secretion
as we found consistent C5a-dependent PKC phosphorylation and
could also show that PKC activation induces CXCL4 secretion
(Fig. 6n, o).
Platelet C5aR1-driven CXCL4 confers the inhibitory effect on
vessel formation. To confirm the relevance of C5a-induced
CXCL4 secretion, we treated endothelial cells with the super-
natant of C5a-stimulated platelets. The addition of supernatant
from C5a-treated WT platelets to endothelial cells resulted in an
Fig. 2 Platelets express C5aR1 and platelet C5aR1 inhibits various endothelial functions. a Isolated washed murine platelets express C5aR1 as assessed
by immune fluorescence microscopy. There was only partial colocalization of C5aR1 (red) with the α-granule marker P-selectin (green). ×630
magnification, scale bars represent 5 µm. Images are representative of four independent experiments. b Histogram showing C5aR1 expression on platelets
(gray curve); the black curves show the histogram obtained with an IgG isotype. The histogram is representative of the analysis of four independent
platelet samples. c Furthermore, flow cytometry revealed that C5aR1 expression on platelets is dynamic. Upon stimulation with CRP, platelet C5aR1
expression increased in WT platelets. In c–e, data are displayed as the mean ± SEM (n= 4 independent experiments) and are shown as the percentage of
control. The expression in the unstimulated WT group represents 100%. *p < 0.05. d Upon stimulation with ADP, WT platelets displayed C5aR1
upregulation at higher concentrations. e Upon treatment with C5a at the indicated concentrations, no significant changes in C5aR1 expression on platelets
could be detected. f Primary lung endothelial cells (MLECs) were grown to a confluent monolayer, which was wounded by scratching with a plastic pipette
and coincubated with C5ar1−/− or WT platelets. The absence of C5aR1 resulted in increased endothelial migration after 17 h. Data are displayed as the
mean ± SEM (n= 6 independent experiments). The area not populated with cells at the start of the experiment minus the area not populated with cells
after 17 h of coincubation with WT platelets represents 100%. *p < 0.05. g Endothelial tube formation by MHEC-5T cells in vitro was significantly increased
after incubation with platelets isolated from C5ar1−/− mice compared platelets isolated from WT mice. Data are shown as the mean ± SEM (n= 4
independent experiments) and displayed as the total tube length after 6.5 h. The cumulative length of endothelial tubes after incubation with WT control
platelets represents 100%. *p < 0.05. h Similarly, endothelial tube formation by MLECs was increased after exposure to C5ar1−/− platelets compared with
WT platelets. Data are shown as the mean ± SEM (n= 4 independent experiments). Tube formation after coincubation with WT control platelets
represents 100%. *p < 0.05. i Representative images of endothelial tube formation of MHEC-5T after coincubation with WT or C5ar1−/− platelets. j The
supernatant of murine WT platelets significantly inhibited tube formation from endothelial spheroids compared with the supernatant of C5ar1−/− platelets.
Data are presented as the mean ± SEM (n= 3 independent experiments) and are shown as the percentage of the total tube length after 24 h in controls.
Tube formation after incubation with WT control platelet supernatant represents 100%. *p < 0.05. k Representative images of sprout formation from
endothelial spheroids in both groups. Scale bar represents 100 μm. l Human platelets were preincubated with a C5aR1 antagonist (PMX53) or control
peptide. Subsequently, platelets were coincubated with human umbilical vein endothelial cells (HUVECs) on Matrigel. Endothelial tube formation was
significantly enhanced by preincubation with PMX53 compared with the control. Data are shown as the mean ± SEM (n= 4 independent experiments with
separate donors) of the total tube length after 6.5 h. The cumulative length of endothelial tubes after incubation with platelets preincubated with control
peptide represents 100%. *p < 0.05. m There was no significant difference in adhesion to endothelial cells under static conditions between WT and C5aR1-
deficient platelets under normoxic conditions. Data are shown as the mean ± SEM (n= 4–5 independent experiments) and as the percentage of control.
Adherent WT platelets expressed as the area fraction of platelet-specific staining divided by the number of endothelial cells expressed as the DAPI count
per area represents 100%. *p < 0.05 compared to control-stimulated platelets. n Representative images of static platelet adhesion of WT and C5ar1−/−
platelets to endothelial cells. Scale bars represent 200 µm. Two-sided Student’s t test in b, f–h, j, l. ANOVA in c–e, m.
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Fig. 3 C5aR1 deficiency promotes ischemia-induced revascularization in vivo. WT or C5ar1−/− mice were subjected to hindlimb ischemia and analyzed
after 2 weeks. a Revascularization of the hindlimbs after femoral artery ligation was visualized by laser Doppler fluximetry (LDI). We found increased
revascularization in C5ar1−/− animals. Data are shown as the mean ± SEM (n= 7 animals per group) and are displayed as the percentage of the perfusion
in the contralateral control limb. *p < 0.05. b Representative LDI images of mouse hindlimbs after femoral artery ligation illustrate increased
revascularization in C5ar1−/− animals compared with WT controls. c Vessel density in the gastrocnemius muscle of the ischemic limbs was quantified by
immunofluorescence staining. Vessels were visualized by isolectin B4 (IB4 in green, nuclei in blue), and images of whole-muscle sections were acquired as
tile scans and analyzed. At 14 days after the induction of ischemia, C5ar1−/− mice exhibited a significantly higher vessel density than WT controls. ×200
magnification, scale bars represent 200 µm. d Quantification of the IB4-positive area fraction in the muscle sections reveals higher vessel abundance in
ischemic C5ar1−/− hindlimbs. Data are shown as the mean ± SEM (n= 10 whole-muscle sections per group) and are displayed as the percentage of
control. The IB4-positive area fraction in WT control hindlimbs represents 100%. *p < 0.001. e Furthermore, WT or C5ar1−/− mice were subjected to
hindlimb ischemia and platelets were depleted systemically by injection of platelet depleting serum starting on the first day post induction of ischemia. We
could not detect significant differences (p < 0.05) in revascularization. Data are shown as the mean ± SEM (n= 7 animals per group) and are displayed as
the percentage of the perfusion in the contralateral control limb. f Vessel density in the gastrocnemius muscle of the ischemic limbs was quantified by
immunofluorescence staining as described in c. At 14 days after the induction of ischemia, WT and C5ar1−/− mice with platelet depletion did not exhibit
significant differences in vessel density. ×200 magnification, scale bars represent 200 µm. Image is representative of 10 whole-muscle sections per group
analyzed. Two-way ANOVA with Bonferroni’s post hoc test in a, e. Two-sided Student’s t test in d.
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Fig. 4 Platelet-specific C5a receptor deletion inhibits revascularization but does not alter platelet deposition in vivo. Pf4-cre+ C5ar1fl/fl mice were
generated as described in the “Methods” section. Hindlimb ischemia was induced, and Pf4-cre− C5ar1fl/fl mice served as controls. a Platelet-specific C5a
receptor 1 knockout mice showed increased revascularization. Data are presented as the mean ± SEM (n= 5 animals per group) and are displayed as the
percentage of the perfusion in the contralateral control limb. *p < 0.05. b Representative LDI images of mouse hindlimbs after femoral artery ligation
illustrate increased revascularization in Pf4-cre+ C5ar1fl/fl mice compared with littermate control animals. c Vessel density in the representative
gastrocnemius muscle sections (vessel marker IB4 in green, nuclei in blue) of the ischemic limbs of Pf4-cre+ C5ar1fl/fl showed significantly higher vessel
density than Pf4-cre− C5ar1fl/fl controls. Scale bars represent 200 µm. d Quantification of the IB4-positive area fraction in the muscle sections reveals
higher vessel abundance in ischemic Pf4-cre+ C5ar1fl/fl hindlimbs at ×200 magnification. Data are shown as the mean ± SEM (n= 10 whole-muscle sections
per group) and are displayed as the percentage of control. The IB4-positive area fraction in Pf4-cre− C5ar1fl/fl hindlimbs represents 100%. *p < 0.05. e By
staining for CD42b (red), platelet deposition was quantified in whole-muscle sections of Pf4-cre+ C5ar1fl/fl or of Pf4-cre− C5ar1fl/fl mice, as described in the
“Methods” section. No difference in the number of platelets per area or microthrombi size was detected. Displayed are representative images for both
genotypes, IB4 staining (green) depicts vascular structures; DAPI (blue) depicts nuclei. Scale bars represent 100 µm. f CD42b-positive single platelets
were quantified by size using automated digital image analysis as described in the “Methods” part in whole-muscle sections. There was no significant
difference between Pf4-cre+ C5ar1fl/fl and Pf4-cre− C5ar1fl/fl mice both with respect of the number of platelets per muscle area as well as the size of the
platelets/microthrombi. Data are shown as the mean ± SEM (n= 6 whole-muscle sections per group) and are displayed as the percentage of control. The
readings in Pf4-cre− C5ar1fl/fl hindlimbs represent 100% in both graphs. *p < 0.05. Two-way ANOVA with Bonferroni’s post hoc test in a. Two-sided
Student’s t test in d, f.
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inhibitory effect on endothelial tube formation (Fig. 7a). This
effect was C5aR1 specific, as the platelet supernatant from C5a-
stimulated C5ar1−/− platelets had no effect (negative control;
Fig. 7a). Addition of CXCL4 to C5a-conditioned C5ar1−/−
supernatant restored the effect of C5a-conditioned WT super-
natant and the supernatant of C5ar1Cxcl4-double-knockout mice
yielded comparable results with C5ar1−/− supernatant (Fig. 7a).
Moreover, endothelial migration was inhibited by C5a-stimulated
WT platelet supernatant (Supplementary Fig. 24a), whereas
proliferation was not affected (Supplementary Fig. 24b). Next, we
depleted CXCL4 from C5a-stimulated WT platelet supernatant
using anti-CXCL4 antibody-coated Sepharose beads. Removal of
CXCL4 from C5a-conditioned platelet supernatant resulted in
significantly increased endothelial tube formation, suggesting that
C5a-driven CXCL4 release is one of the central factors mediating
the antiangiogenic role of platelets (Fig. 7b). In C5ar1−/− platelet
supernatant, CXCL4 depletion had no effect (Fig. 7b). As C5a was
shown to induce phosphorylation of PI3K, Akt, and PKC
(Fig. 6n–q), we tested whether preincubation of platelets with the
according kinase inhibitors followed by C5a stimulation could
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impede the inhibitory effect of C5a-conditioned platelet super-
natant on endothelial tube formation. Indeed, we found no sig-
nificant differences between tube formation with vehicle control-
stimulated platelet supernatant and C5a-conditioned platelet
supernatant from platelets preincubated with Akt, PI3K, and PKC
kinase inhibitors (Fig. 7c).
To further assess the role of CXCL4 in platelet C5aR1-
mediated inhibition of angiogenesis, we isolated primary murine
lung endothelial cells from Cxcr3−/− mice. CXCR3 has been
described as the endothelial receptor that mediates antiangiogenic
effects of CXCL435. The supernatant from C5a-stimulated WT
platelets did not inhibit endothelial migration (Fig. 7d) and tube
formation (Fig. 7e) in Cxcr3−/− cells compared with vehicle
control-stimulated WT platelet supernatant, whereas this effect
was present using WT endothelial cells (Fig. 7d). Moreover, we
observed no increased endothelial tube formation of Cxcr3−/−
endothelial cells using supernatant from C5a-conditioned versus
vehicle control-stimulated C5ar1−/− platelets (Fig. 7e).
We continued to study the mechanisms, by which platelets
control angiogenesis after C5a stimulation in vivo using a mouse
model, which allowed us to selectively add C5aR1+ or C5aR1-
platelets. For this purpose, we used the in vivo Matrigel plug
assay, in which vessel ingrowth into an extracellular matrix-like
gel, which is subcutaneously injected into mice, is stimulated by
endothelial growth factors12. Similar to ischemic hindlimb tissue
(Fig. 1a), we observed complement activation upon induction of
vessel growth, as verified by the deposition of C3b (Fig. 7f).
Having confirmed the presence of complement activation, we
considered the Matrigel plug assay a suitable model to further
determine the functional role of platelets in vessel formation.
Consistent with our findings of improved revascularization after
induction of hindlimb ischemia as a consequence of C5aR1
deficiency (Fig. 3), Matrigel plugs in C5ar1−/− mice displayed a
larger area of neovascularization after 7 days, indicating a higher
level of angiogenic factor-induced vessel growth (Fig. 7g). To
further delineate the cell-specific role of C5aR1 on platelets, we
resuspended freshly isolated murine platelets in
Matrigel supplemented with basic fibroblast growth factor
(bFGF). WT platelets inhibited growth factor-induced
angiogenesis in C5ar1−/− mice, which could not be observed
for C5ar1−/− platelets (Fig. 7h). Next, we injected Matrigel into
C5ar1−/− mice and supplemented it with WT platelets or
platelets isolated from Cxcl4−/− animals. Compared to Cxcl4−/−
platelets, WT platelets inhibited growth factor-induced angiogen-
esis in C5ar1−/− mice (Fig. 7i). In another set of experiments, we
systemically inhibited CXCL4 by intravenous injection of an anti-
CXCL4 blocking antibody or control IgG as previously
described36. Matrigel plugs from C5ar1−/− mice supplemented
with WT platelets displayed an increased level of growth factor-
induced angiogenesis when CXCL4 was inhibited compared to
controls (C5ar1−/− mice supplemented with WT platelets+ IgG
injection; Fig. 7j). Finally, we examined whether the C5a–C5aR1
axis can be influenced pharmacologically in the context of vessel
growth. Matrigel was supplemented with the C5aR1 antagonist
PMX53 or the respective control peptide. C5aR1 inhibition
resulted in an increase of growth factor-induced angiogenesis as
compared to control (Fig. 7k, l).
In the hindlimb ischemia model, we detected CXCL4
deposition in muscle tissue 1 week after induction of ischemia
and CXCL4 was deposited outside of vessels (Fig. 7m). Interest-
ingly, we detected significantly lower levels of CXCL4 in
homogenized hindlimb muscles of C5ar1−/− mice subjected to
hindlimb ischemia than in those of WT littermate controls
(Fig. 7o). These findings strongly support our hypothesis that
C5a-induced CXCL4 is an important negative regulator of
ischemia-induced revascularization in vivo. Analyzing histologi-
cal sections, we found significantly less CXCL4 deposition in
C5ar1−/− mice (Fig. 7m, n). When we specifically targeted C5aR1
with the C5aR1-specific antagonist PMX205 in vitro, C5a-
induced CXCL4 secretion from platelets was completely abro-
gated (Fig. 7p). Moreover, using the C5aR1 antagonist PMX205
in vivo, we observed that revascularization was significantly
increased during days 4–10, when C5aR1 was inhibited (Fig. 7q),
whereas PMX205 had no effect on tail bleeding time (Supple-
mentary Fig. 25).
In conclusion, we provide evidence for a functional crosstalk
between cells of hemostasis with the innate immune system
during tissue revascularization. More specifically, we demonstrate
Fig. 5 C5aR1 deficiency on platelets induces increased collateral artery formation, capillarization, and pericyte coverage. Platelet-specific C5aR1-
deficient mice were subjected to hindlimb ischemia. To visualize collateral arteries, mice were perfused with a contrast agent at d9 after induction of
ischemia and subjected to microCT analysis as described in the “Methods” section. a 3D reconstructions of arteries from Pf4-cre− C5ar1fl/fl mice showed
collateral artery formation, while the main femoral artery (arrows) was no longer perfused. a, b A comparison of collateral artery formation in mice with
C5aR1-deficient or -competent platelets shows increased collateralization in platelet-specific C5ar1-knockout mice. Images are representative of 3–4 mice,
i.e., 3–4 vessel trees analyzed. c The size distribution of vessels within the ischemic hindlimbs of Pf4-cre+ C5ar1fl/fl mice and Pf4-cre− C5ar1fl/fl mice was
quantified within the microCT data in mouse hindlimbs proximal to the knee in the region of the adductor muscle (for details on methodology, please refer
to the “Methods” section and Supplementary Fig. 8). Pf4-cre+ C5ar1fl/fl mice displayed larger vessels in both the small vessel range as well as the medium-
sized vessel range. Data are shown as overlaid single measurements of each of the 3–4 vessel trees analyzed and as mean ± 95% confidence interval of all
vessels quantified within each size region (n= 3–4 animals, i.e., vessel trees per group). Data are stated in pixels/voxels and 1 voxel represents 21.6 µm.
Furthermore, the mean vessel diameter shows a clear trend that vessels in the proximal part of the ischemic hindlimb are larger in Pf4-cre+ C5ar1fl/fl mice
compared to controls (right) going along with improved revascularization. d Characterization of arteries in the distal ischemic hindlimb gastrocnemius
muscle of Pf4-cre+ C5ar1fl/fl or Pf4-cre− C5ar1fl/fl mice reveal no significant differences in large artery size or abundance of arterioles (SMA in red, vessel
marker IB4 in green). ×200 magnification, scale bars represent 200 µm, arrows mark large muscle arteries double positive for SMA and IB4. e Large distal
muscle arteries were assessed by measuring the perimeter of the 5 largest arteries present in a whole-muscle section acquired by tile scanning at ×200
magnification (left). Furthermore, the area fraction in the muscle sections of SMA-positive vessels was quantified at ×200 magnification. Data are shown
as the mean ± SEM (n= 10 whole-muscle sections per group) and are displayed as the percentage of control. The sum of artery perimeters of the five
largest arteries per section or the area fraction of SMA staining in Pf4-cre− C5ar1fl/fl hindlimb muscle sections represent the 100% control. n.s.= no
significant difference was observed. f Platelet-specific C5ar1-knockout mice displayed increased pericyte coverage of vessels in the ischemic muscle tissue
at d14 after induction of ischemia. (pericyte marker NG2 in red, vessel marker IB4 in green). ×200 magnification, scale bars represent 200 µm. g Pericyte
density was assessed by measuring the area fraction of NG2-positive staining in whole-muscle sections acquired by tile scanning at ×200 magnification
(left). Furthermore, pericyte coverage was assessed by calculating the spatial colocalization of NG2 and IB4 staining. Data are shown as the mean ± SEM
(n= 10 whole-muscle sections per group) and are displayed as the percentage of control. The area fraction of NG2 staining or the pericyte coverage in Pf4-
cre− C5ar1fl/fl hindlimb muscle sections represent 100%. *p < 0.05 or <0.01. Two-sided Student’s t test in e, g.
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that platelet C5aR1 inhibits endothelial functions in vitro and
decreases growth factor-induced angiogenesis and ischemia-
induced revascularization in vivo. Mechanistically, we identify
platelet-derived CXCL4 production and secretion downstream of
C5a/C5aR1 axis activation as a secretory pathway, by which
platelets control vessel formation.
Discussion
Although both complement components and platelet-derived
mediators contribute to the regulation of vessel
formation9–12,18,25–27,29,37–43, a functional intersection between
platelets and the complement system in the context of revascu-
larization has not been investigated so far. Here we characterized
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a role for the anaphylatoxin receptor C5aR1 expressed on plate-
lets in ischemic and revascularizing tissue. We found that (i)
platelets modulate specific endothelial functions relevant for
angiogenesis through C5aR1, (ii) platelet C5aR1 mediates an
inhibitory effect on collateral artery formation in ischemia-
induced revascularization and (iii) capillary formation and peri-
cyte coverage, (iv) platelets release CXCL4 upon C5a stimulation,
and (v) the platelet C5aR1-mediated effect on vessel formation is
mediated by preferential CXCL4 release in vitro and in vivo.
C5a receptor 1 is expressed on immune cells, epithelial cells,
and endothelial cells8. Interestingly, complement anaphylatoxin
receptors have been reported to be expressed on platelets21,24,
which are cells of the hemostatic system, and their expression
correlates with platelet activation markers in atherosclerosis, a
disease featuring vascular inflammation22. Platelets express a
variety of complement-regulating proteins (reviewed in ref. 44). In
this study, we observed an increased presence of platelets in
revascularizing tissue, and we detected the anaphylatoxin receptor
C5aR1 on platelets within angiogenic tissue. Future studies
should address whether platelets or platelet-derived factors can be
useful as biomarkers to detect or characterize angiogenic tissue45.
Importantly, we demonstrated the importance of platelet C5aR1
for endothelial functions in vitro and neovascularization in vivo
using approaches of platelet reconstitution and pharmacological
Fig. 6 Platelet C5aR1 mediates release of the paracrine effector CXCL4 in an Akt- and PKC-dependent fashion. aWashed murine WT platelets carefully
isolated with inhibitors of platelet activation were stimulated with C5a. The supernatant was analyzed by a membrane-based antibody array. Specific
mediators, such as CXCL4 (red circles), were upregulated after stimulation with C5a (bottom) compared with the vehicle control (top). b Results of four
array repeats were quantified. For most factors, C5a stimulation (gray) induced a slight upregulation compared to vehicle control (black). The strongest
increase was observed for CXCL4. Data are shown as the mean ± SEM (n= 4 independent experiments) and are displayed as intensity values. *p < 0.05.
Bonferroni’s post hoc analysis was performed; results are displayed in Supplementary Fig. 9. c Single-cell staining revealed that murine platelets are
activated upon C5a stimulation and release CXCL4. Upon stimulation with ADP and C5a, a ring-like staining pattern was observed, indicating platelet
activation (arrows). However, C5a-stimulated platelets exhibit reduced CXCL4 content after stimulation with C5a, which cannot be observed to the same
extent in the ADP-stimulated group. ×630 magnification, scale bars represent 5 µm. Images are representative of four independent experiments.
d Quantification of P-selectin intensity in each platelet reveals upregulation, indicating platelet activation upon stimulation with ADP and C5a. However, no
significant difference was detected between ADP and C5a. Data are shown as the mean ± SEM (n= 5 images analyzed) and are displayed as the
percentage of control. The P-selectin intensity in vehicle control-stimulated WT platelets represents 100%. *p < 0.05 e Quantification of CXCL4 intensity in
relation to P-selectin intensity in each platelet reveals relatively stronger secretion of CXCL4 upon C5a stimulation compared to ADP. Data are shown as
the mean ± SEM (n= 5 images analyzed) and are displayed as the percentage of control. The CXCL4 intensity in relation to P-selectin intensity in vehicle
control-stimulated WT platelets represents 100%. *p < 0.05. f Single platelets from mice were stimulated with C5a or vehicle control. Granules were
quantified by calculating the area of predominantly green staining within the platelets (P-selectin-predominant), predominantly red areas (CXCL4-
predominant) as well as overlayed yellow areas (P-selectin-CXCL4 double positive). ×630 magnification, scale bars represent 1 µm. Images are
representative of >100 analyzed single platelets. g As described in Supplementary Fig. 10, granule area fractions were quantified. We observed a distinct
distribution pattern of granules, with a similar amount of CXCL4-predominant as well as P-selectin-CXCL4 double-positive granules and a significantly
lower number of P-selectin-predominant granules, which contain P-selectin over CXCL4. Data are shown as the mean ± SEM (n= 112 single platelets
analyzed) and are displayed as the area fraction. p (CXCL4 versus double positive) < 0.001, p (CD62P versus double positive)= 0.0022. h Upon
stimulation with C5a, analysis revealed a reduction in CXCL4-predominant granules, while the area fraction of double-positive granules remains
unchanged, while the relative area fraction of P-selectin predominant granules increases, thus demonstrating C5a-induced secretion of a subset of α-
granules, which contain CXCL4 over P-selectin. Data are shown as the mean ± SEM (n= 166 single platelets analyzed) and are displayed as the area
fraction. p (CD62P versus CXCL4) < 0.001. i Conventional ELISA confirmed a significant dose-dependent increase in CXCL4 secretion from human
platelets after C5a stimulation. Maximum CXCL4 release is reached at a C5a concentration of 2000 ng/ml. Data are shown as the mean ± SEM (n= 8
independent experiments containing separate donors) and are displayed as the percentage of control. The CXCL4 protein level of vehicle-stimulated
platelet supernatant represents 100%. *p < 0.05. j Murine megakaryocytes from WT versus C5ar1−/− mice were assessed for distribution of CXCL4-
predominant granules (red). Displayed are representative images, nuclei are shown in green. ×630 magnification, scale bars represent 10 µm. k As
described in Supplementary Fig. 10, granule area fractions were quantified in megakaryocytes from WT versus C5ar1−/− mice. No significant difference
could be detected for CXCL4-predominant granules. Data are shown as the mean ± SEM (n= 10–12 single megakaryocytes analyzed) and are displayed as
the area fraction. l RT-PCR analysis detected similar mRNA levels of CXCL4 in megakaryocytes from WT versus C5ar1−/− mice. Data are presented as the
mean ± SEM (n= 5 independent experiments) and are shown as relative expression in relation to GAPDH. m Citrated whole blood from WT and C5ar1−/−
mice was stimulated using different concentrations of C5a (20, 200, 2000 ng/ml) and vehicle control and assessed for platelet activation markers by flow
cytometry. For the gating strategy, please refer to the “Methods” section. Activated platelets are detected as CD62PJONA++, whereas JONA detects
activated GPIIbIIIa. C5a induced platelet activation in WT platelets but not in C5ar1−/− platelets. Data are shown as the mean ± SEM (n= 4 independent
experiments) and are displayed as the percentage of control. The percentage gated CD62PJONA++ platelets in the vehicle-stimulated group represents
100%. *p < 0.05. n In order to uncover the signaling downstream of C5aR1 leading to CXCL4 secretion, lysates of WT platelets were generated after vehicle
control or C5a stimulation and samples were probed at equal protein concentrations for phospho-proteins as well as non-phosphorylated controls. Platelet
C5aR1 ligation induced reproducible PKC substrate phosphorylation (PKC phosphor Ser). As a control, we used the PKC activator PMA. PKC activation was
quantified by dividing the phosphorylation signal by the total protein signal as well as unphosphorylated PKC α (Supplementary Fig. 23). Displayed are
representative images of at least four independent experiments. o We also checked whether PKC activation also entails CXCL4 release by stimulating
washed platelets with C5a and PMA. Both C5a and PMA induced significant CXCL4 release. Data are shown as the mean ± SEM (n= 5–16 independent
experiments) and are displayed as the percentage of control of CXCL4 concentration in platelet supernatant measured by ELISA. The mean fluorescence
intensity (MFI) of platelets in the vehicle-stimulated group represents 100%. *p < 0.01. p Furthermore, C5a induced an upregulation of phosphorylated Akt
(Ser473), PI3K (Ser 47), GSK-3β (Ser 9), p44/42 MAPK (Thr202/Tyr204), PLCβ3 (Ser537). Displayed are representative images of at least four
independent experiments. For quantification of phosphorylation, please refer to Supplementary Fig. 23. q Interestingly, C5a induced no regulation of
phosphorylated PLCγ2 (Tyr1217) and PKA (α/β/γ catalytic subunit phospho T197). Activated Rap1 (Rap1-GTP) was analyzed using a Rap1 pulldown assay.
No significantly altered amounts of Rap1-GTP could be detected. Displayed are representative images of at least four independent experiments. One-way
ANOVA with Bonferroni’s post hoc test in b, d, e, g–i, m. Two-sided Student’s t test in k, l, o.
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inhibition. Furthermore, we generated a platelet-specific C5aR1-
deficient mouse model to specifically assess the platelet C5aR1-
mediated effects.
The antiangiogenic relevance of platelets or platelet-derived
mediators has been suggested for tumor angiogenesis. During the
early stages of tumor growth, it was observed that platelet-derived
thrombospondin 1 serves as a negative regulator of
angiogenesis38. Here we identified a complement-driven release
mechanism for the platelet-derived chemokine CXCL4 as an
inhibitor of vessel formation in vivo as well as endothelial func-
tions in vitro. Italiano et al. and others showed that various
proangiogenic and antiangiogenic factors are stored in distinct
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subpopulations of platelet α-granula and that these factors can be
released differentially in response to specific stimuli25,27. How-
ever, our understanding of the mechanisms underlying this tai-
lored secretion is poor. Angiostatin release from platelets, for
example, follows different kinetics than VEGF secretion during
thrombus formation46. Furthermore, proteinase-activated recep-
tors 1 and 4 can counter-regulate endostatin and VEGF release
from human platelets47. Here we identified the C5a/C5aR1 axis
not only as a potent inducer of platelet activation but also
demonstrate that this pathway drives the release of CXCL4, an α-
granule component, which only partially colocalizes with other α-
granule components, such as P-selectin.
Platelets contain both proangiogenic and antiangiogenic
factors27. Accordingly, platelets have also been described as
Fig. 7 Platelet C5aR1-induced inhibition of neovascularization is dependent on the secretion of CXCL4. a MHEC-5T were coincubated with the C5a-
stimulated supernatant of platelets isolated from WT, C5ar1−/−, and C5ar1−/−Cxcl4−/− mice. Furthermore, the supernatant of C5ar1−/− platelets was
supplemented with CXL4 (2 µg/ml). C5a-stimulated WT platelet supernatant inhibited endothelial tube formation, which was not detectable in C5ar1−/−
and C5ar1−/−Cxcl4−/− platelets. Reconstitution with CXCL4 in the C5ar1−/− group led to a similar level of tube formation as in the WT group. Data are
displayed as the mean ± SEM (n= 5 independent experiments). The total tube length after treatment with vehicle-stimulated platelet supernatant
represents 100%. *p < 0.05. b CXCL4 was immunodepleted from C5a-stimulated WT as well as C5ar1−/− platelet supernatant, and the impact of this
supernatant on endothelial tube formation was assessed. Data are shown as the mean ± SEM (n= 5 independent experiments). The total tube length in the
group with control-depleted supernatant from C5a-stimulated C5ar1−/− platelets represents 100%. *p < 0.05. c Freshly isolated washed murine WT
platelets were preincubated with vehicle control or kinase inhibitors SH-6, Wortmannin, and Gö976 before stimulation with C5a. The supernatant was then
coincubated with MHEC-5T and endothelial tube formation was quantified. Preincubation of platelets with SH-6, Wortmannin, and Gö976 led to a level of
tube formation not significantly different from vehicle control-stimulated WT platelet supernatant. Data are shown as the mean ± SEM (n= 4–8
independent experiments). The total tube length in the group with control-preincubated vehicle control-stimulated WT platelet supernatant represents
100%. *p < 0.05. d Primary murine lung endothelial cells were isolated from Cxcr3−/− mice (for endothelial cell quality control refer to Supplementary Fig.
3). After coincubation with C5a-stimulated platelet supernatant, WT endothelial cells displayed decreased endothelial migration in the scratched wound
assay. Cxcr3−/− endothelial cells exhibited a significantly smaller decrease in migration compared with WT cells. Data are displayed as the mean ± SEM
(n= 6 independent experiments). Migration in the WT endothelial cell group treated with vehicle-stimulated WT platelet supernatant subtracted
represents 100%. *p < 0.05. e Similarly, the decrease in endothelial tube formation was significantly smaller in Cxcr3−/− endothelial cells following
coincubation with C5a-stimulated platelet supernatant compared with control supernatant and comparable to the level C5ar1−/− platelet supernatant
stimulated with C5a. Data are shown as the mean ± SEM (n= 5 independent experiments). The total tube length in the group treated with vehicle-
stimulated WT platelet supernatant represents 100%. *p < 0.05. f Similar to the hindlimb ischemia model (Fig. 1a), complement activation (C3b, red)
colocalized with vascular structures (IB4, green) within the Matrigel plug 7 days after implantation. ×400 magnification. Scale bars represent 100 µm.
Displayed is a representative image of four independent experiments. g To study the paracrine effect of platelets after C5a stimulation in vivo, we used the
Matrigel model to analyze vascularization after the addition of platelets and soluble mediators. Matrigel was supplemented with bFGF and injected into WT
or C5ar1−/− mice. Quantification of neovascularization after 7 days yielded a significantly higher level of growth factor-induced angiogenesis in C5ar1−/−
animals than in WT controls. Data are shown as the mean ± SEM (n= 6–8 Matrigels per group). The neovascularization area fraction within Matrigels
from WT mice represents 100%. *p < 0.05. h Freshly isolated WT or C5ar1−/− platelets were resuspended in Matrigel, the Matrigel was implanted into
C5ar1−/− animals, and vascularization was assessed after 7 days. Data are presented as the mean ± SEM (n= 7–8 Matrigels per group). The
neovascularization area fraction in Matrigels from C5ar1−/− mice supplemented with C5ar1−/− platelets represents 100% expressed as the area fraction of
nuclear staining. *p < 0.05. i WT platelets or Cxcl4−/− platelets were coinjected with Matrigel into C5ar1−/− animals. Injection of Cxcl4−/− platelets or
vehicle control yielded similar levels of growth factor-induced vessel formation. However, injection of WT platelets significantly reversed the phenotype of
increased neovascularization in C5ar1−/− mice. Data are shown as the mean ± SEM (n= 6 Matrigels per group). The neovascularization area fraction in
Matrigels from C5ar1−/− mice re-transfused with vehicle control represents the 100% value expressed as the area fraction of nuclear staining. *p < 0.05,
WT platelets versus Cxcl4−/− platelets. j WT platelets were coinjected with Matrigel into C5ar1−/− mice, and animals were treated systemically with an
anti-CXCL4 antibody or IgG control. While the animals that received WT platelets and IgG control showed a reduced level of growth factor-induced
angiogenesis, the animals that received WT platelets and anti-CXCL4 antibody did not exhibit significantly different vessel formation levels compared with
control animals that did not receive platelet retransfusion. Data are shown as the mean ± SEM (n= 7–9 Matrigels per group). The neovascularization area
fraction in Matrigels from WT mice without platelet injection and vehicle control treatment represents 100% expressed as the area fraction of nuclear
staining. *p < 0.001, anti-CXCL4 antibody versus IgG control. kMatrigel was supplemented with bFGF and additionally PMX53 or PMX control and injected
into WT mice. Quantification of neovascularization after 7 days yielded a significantly higher level of growth factor-induced angiogenesis in the PMX53
group. Data are shown as the mean ± SEM (n= 7 Matrigels per group). The neovascularization area fraction within Matrigels fromWT mice supplemented
with PMX control represents 100%. *p < 0.05. l Representative immunofluorescent stainings of Matrigel plug sections at ×400 magnification shows
Matrigel neovascularization (IB4 in green, nuclei in blue) is increased after supplementation of Matrigel with PMX53. Scale bars represent 100 µm. Image is
representative of at least four analyzed plugs. m Ischemic hindlimb muscle tissue from WT or C5ar1−/− mice was stained for the presence of CXCL4
deposition (red) 1 week after induction of ischemia. IB4 staining (green) depicts vascular structures, DAPI (blue) nuclei. ×630 magnification, scale bars
represent 2 µm. n Quantification of CXCL4 abundance by measuring the area fraction of CXCL4-positive staining in whole-muscle sections acquired by tile
scanning at ×400 magnification. Data are shown as the mean ± SEM (n= 10 whole-muscle sections per group) and are displayed as the percentage of
control. The area fraction of CXCL4 staining in hindlimb muscle sections from WT mice represents 100%. *p < 0.01. o Ischemic muscle tissue from the
hindlimb ischemia experiments was homogenized, and samples of equal protein content were probed for CXCL4 concentration using ELISA. Homogenates
from C5ar1−/− mice yielded significantly lower CXCL4 levels compared with those from WT mice. Data are shown as the mean ± SEM (n= 6–8 muscles
processed). The CXCL4 concentration in WT muscle homogenates measured by ELISA represents 100%. *p < 0.05. p Freshly isolated washed murine WT
platelets were isolated and preincubated with PMX205 or vehicle control. C5a-induced CXCL4 secretion was quantified by ELISA. PMX205 inhibited C5a-
induced CXCL4 secretion. Data are shown as the mean ± SEM (n= 5–25 independent experiments). The CXCL4 concentration in the supernatant of WT
platelets stimulated with vehicle control represents 100%. *p < 0.05. q WT mice treated with the C5aR1 inhibitor PMX205 or control were subjected to
hindlimb ischemia and analyzed after 2 weeks. We observed increased revascularization in PMX205-treated animals. Data are shown as the mean ± SEM
(n= 7 animals per group) and are displayed as the percentage of the perfusion in the contralateral control limb. *p < 0.05 Two-sided Student’s t test in
g–k, n, o. One-way ANOVA with Bonferroni’s post hoc test in a–e, p. Two-way ANOVA with Bonferroni’s post hoc test in q.
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proangiogenic mediators in conditions, such as ovarian cancer48.
In fact, platelet-derived products are used by clinicians to foster
healing in orthopedic patients48,49, partially due to their proan-
giogenic properties. Here we observed a specific inhibitory effect
of platelet C5aR1 in ischemia-induced revascularization. Fur-
thermore, platelets are important for the prevention of excessive
hemorrhage from newly formed vessels39. The net effect that
platelets have on vessel formation may depend on the sur-
rounding microenvironment or other factors, which should be
further characterized in future studies.
Complement activation in ischemia–reperfusion injury (IRI) is
well characterized (reviewed in ref. 50). However, this work shows
complement deposition in hindlimb ischemia tissue without
reperfusion. Reactive oxygen species (ROS) production is regar-
ded as the main driver of complement activation in IRI by the
classical pathway. Most likely, this mechanism also applies to the
hindlimb ischemia model, where ROS production plays a critical
role even in the absence of reperfusion51. Furthermore, the acti-
vated endothelium in the ischemic tissue may bind gC1qR and
thereby activate the classical complement pathway52,53.
The complement system is known to be involved in the regulation
of angiogenesis8,12,18. An inhibitory role of C5aR1 on revasculariza-
tion is in accordance with previous reports10,12. In an earlier study,
we showed that C5aR1 inhibits angiogenesis through the secretion of
soluble VEGF receptor 1 (sVEGFR1) from macrophages.
Complement-mediated release of sVEGFR1 has been described to be
clinically relevant in placental dysfunction10. How does this reconcile
with our current finding that the complement-mediated inhibition of
neovascularization is also dependent on platelets? Vessel formation
and growth are ubiquitous mechanisms in organisms and require a
finely balanced equilibrium of proangiogenic and antiangiogenic
stimuli from different cells54. Thus, several cell types may utilize the
complement system as a means to modulate angiogenesis and
revascularization. The complement system is one of the ontogeneti-
cally oldest plasma protein systems and mediates crosstalk among
various cell systems in immunity and tissue repair processes1.
Other studies have reported a decreased level of angiogenesis in
C5ar1−/− mice9 and in mice deficient in complement factor 355.
These studies investigated the role of the complement system in
laser-induced choroidal neovascularization, a model for age-
related macular degeneration, in which the retinal pigment epi-
thelium plays a unique pathophysiological role56. Given the
versatility of the complement system, it is possible that it regulates
angiogenesis in a context-dependent manner, such as stimulating
angiogenesis in the eye but eliciting different effects in other
tissues and experimental models.
In the present study, we identified a mechanism underlying the
inhibitory role of platelet C5aR1 in revascularization. The anti-
angiogenic factor CXCL457,58 is released from platelets upon
stimulation with C5a and mediates this effect in a receptor-
specific manner as verified by in vitro and in vivo approaches. At
this point, we cannot rule out that other platelet factors besides
CXCL4 released upon C5a stimulation mediate the observed
revascularization-modulating effects. These factors will have to be
identified and studied in future investigations.
CXCL4 is a pro-coagulant, which binds and neutralizes heparins
and thus impacts not only on hemostasis but also acts as an inhibitor
of angiogenesis. The functions of CXCL4 in vascular homeostasis are
complex. In vivo studies using various transgenic mouse models
demonstrated an important role for CXCL4 in thrombosis. Neu-
tralization of CXCL4 identified its central role for the anticoagulant
effect of heparins59. Others have shown in a primate model that
physiologically relevant concentrations of CXCL4 stimulate the
generation of activated protein C (APC), which suggests that CXCL4
plays a previously underappreciated role in the soluble coagulation
cascade60. As one of the underlying mechanisms, it was suggested
that CXCL4 binds with relative high specificity and high affinity to
thrombomodulin and protein C, interactions which may enhance the
affinity of the thrombin–thrombomodulin complex for protein C,
thereby promoting the generation of APC61. Interestingly, CXCL4
can alter the structure of fibrin, thereby contributing to the sealing of
blood clots62.
Previous findings identified C3a and C5a as activators of pla-
telet activation, aggregation of gel-filtered human platelets as well
as serotonin release63,64. For C5a, we detected increased platelet
activation; however, we found no significant dense granule release
from murine platelets. At this point, we cannot entirely explain
why C5a induces a2b/b3 integrin activation but not aggregation.
Further profound studies are needed to characterize this obser-
vation. It is well appreciated that C5 deficiency protects mice
from lethal thrombosis. Mice lacking C5 experience milder
thrombocytopenia, consumptive coagulopathy, and liver injury
than C5-competent mice in a model of histone-induced liver
injury65. We found that C5-deficient platelets secrete CXCL4
upon C5a stimulation. Interestingly, the absence of C5aR1 had no
effect on in vivo hemostasis or bleeding time in our study sug-
gesting an effect on revascularization, which is distinct from the
hemostatic functions of activated platelets.
Strikingly, we observed that targeting CXCL4 was sufficient to
block the effect of platelet C5aR1 on vessel formation. These findings
suggest that C5aR1-transmitted effects can be blocked pharmacolo-
gically and that CXCL4 is the predominant angiogenic factor released
upon C5a stimulation of platelets. However, at this point, we cannot
entirely rule out that in addition to CXCL4 other platelet factors are
released upon C5a stimulation and contribute to the observed
revascularization-modulating effects.
The C5a receptor 1 is a seven transmembrane G protein-
coupled receptor, which transmits its signals via the Gβγ subunit
that induces PI3Kγ-dependent Akt phosphorylation and the Gαi
subunit, leading to PKA activation66. Overall, C5aR1-dependent
signaling is complex involving PI3K and Akt-dependent path-
ways, PKC and MAPKs, IκBα, NfκB, and sphingosin 1 phosphate
(S1P)67. In T cells, it has been shown that C5aR1 transmits its
signal via PI3K and Akt68,69. In neutrophils, C5a-induced PI3K
signaling has been demonstrated70, in macrophages PI3K, Akt,
MEK1/2, and ERK1/2 signaling71. Furthermore, PLCβ has been
implicated in C5aR1 signaling, particularly if PKC is involved72.
Here we demonstrate a signaling pathway involving PI3K, Akt,
PLCβ3, PKC, and Erk1/2. No C5a-dependent signal in platelets
was detected for PLCγ2, PKA, and Rap-1. This is important, as
the C3aR has been shown to signal via Rap1 in platelets,
recently23,24. A PI3K- and Akt-dependent pathway leading to
PKC activation has already been observed for platelets, such as in
PAR-1-driven CXCL12 release73.
We found an increased abundance of CXCL4 in ischemic
muscle tissue of C5aR1-deficient mice. Platelets are the major
source of CXLC4 in organisms74. In vitro, we identified CXCL4 as
the major component released from platelets in response to C5a
stimulation mediating the inhibitory effect on endothelial func-
tions, such as tube formation and migration. This effect of
CXCL4 is in accordance with previous findings75. In vivo,
arteriogenesis or collateral artery outgrowth is considered the
primary mechanism responsible for hindlimb revascularization
after femoral artery ligation76. Indeed, we observed increased
collateral artery formation in platelet-specific C5aR1-deficient mice
associated with their phenotype of enhanced revascularization. We
observed differences in hindlimb revascularization between the
assessed genotypes (WT versus C5ar1−/− or Pf4-cre+/− C5ar1fl/fl)
after the onset of ischemia. Although we have quantified the
vascular network in nonischemic control limbs, we cannot, at this
point, entirely rule out that platelet C5aR1 impacts also on the
formation of pre-existent collaterals in the mouse hindlimb.
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While in the distal hindlimb no differences in artery size or
number could be detected, we noted differences in vessel density
indicating an additional angiogenesis-related process. This is in
accordance with recent reports attributing an important addi-
tional role to angiogenesis in hindlimb revascularization77.
A key to understanding the phenotype of ameliorated revas-
cularization in platelet-specific C5aR1-deficient mice might be the
increased presence and an amplified coverage of vessels with
pericytes, which we observed in platelet-specific C5aR1-deficient
animals. Pericytes have been shown to express CXCR3, the
receptor for CXCL478. Exploring the effect of the C5aR1-CXCL4
axis on pericyte biology might be a very interesting avenue for
future studies, as pericytes have also been implicated as mediators
of tissue injury after acute ischemic events, such as myocardial
infarction79.
Our observations could be of clinical relevance because tar-
geting angiogenesis has become an important therapeutic
approach for treating cancer and vascular diseases, such as
myocardial infarction54,80. Modulation of the complement system
is recognized as a promising strategy in drug discovery81. The
complement system has been demonstrated to be a promising
therapeutic target for a growing number of clinical conditions
including paroxysmal nocturnal hemoglobinuria (PNH)82,83 and
atypical hemolytic uremic syndrome84. The C5 blocking mono-
clonal antibody (mAb) eculizumab has been successfully used for
PNH for >10 years and a specific C5aR1 antagonist (avacopan)
has been filed for Food and Drug Administration approval for the
treatment of antineutrophil cytoplasmic antibody-associated
vasculitis. Translational studies showed that inhibition of C5a
and the C5b–9 complex inhibits leukocyte and platelet activation
during extracorporeal circulation85. Regarding the soluble coa-
gulation system, C5a was suggested as a pharmacological target to
treat patients with sepsis, as this approach countered the
impairment of the homeostasis between coagulation and
fibrinolysis86. Moreover, a large number of additional therapeutic
modalities that target the complement system are currently in the
pharmaceutical pipeline87. Finally, the complement system has
been evaluated as a therapeutic approach at the preclinical level in
a number of immunological and cardiovascular diseases, such as
arthritis88, sepsis89, IRI90, fetal injury in antiphospholipid
syndrome91, and abdominal aortic aneurysm92. Whether strate-
gies of revascularization targeting the C5aR1 are beneficial in
these clinical settings will have to be addressed in further studies.
Here we successfully targeted C5aR1 in vivo using a C5aR1
antagonist resulting in increased vessel formation. Applying
inhibitors of the complement system that inhibit the C5a/C5aR1
axis may be a promising approach to shift the platelet-mediated
response in ischemic diseases such as coronary or peripheral
artery disease toward increased revascularization.
In conclusion, our findings emphasize a role for platelets and
the complement system in vessel formation and identify the
C5aR1–CXCL4 axis as an intersection point between these three
systems.
Methods
Mice. All animal procedures were approved by the regional animal care and use
committee of the District of Tübingen, Baden-Württemberg (Konrad-Adenauer-
Straße 20, 72072 Tübingen, Germany). All animal experiments were performed in
accordance with the German law guidelines of animal care. C57BL/6 (WT) mice
were originally acquired from Jackson Laboratories but were bred in our own
animal facility. Here the light cycle was 12 h, temperature 20–22 °C, humidity
40–60%. C5aR1-deficient mice (CD88, C5ar1−/−) have been previously described
elsewhere93; they were kindly provided by Dr. C. Gerard (Harvard Medical School,
Boston, MA, USA) and bred in our animal facility on the C57BL/6 background.
Furthermore, we used mice deficient for C5 (B6(Cg)Tg(Ins2-GP)zbz) bred in the
animal facility of the University of Lübeck (Germany), which have been described
previously94. Mice deficient in C5aR2 as well as tdTomato-C5aR2fl/fl knock-in mice
were described previously34. Furthermore, C3aR-deficient mice (B6.129×1-
C3ar1tm1Raw) were used95. Mice deficient for the CXC chemokine receptor 3
(CD183, Cxcr3−/−) were purchased from Jackson Laboratories and have been
previously described elsewhere96. Mice deficient in CXCL4 (Cxcl4−/−) were gen-
erated and kindly provided by Dr. P. von Hundelshausen (IPEK, Munich, Ger-
many) and have been previously described elsewhere97. Briefly, Cxcl4−/− mice were
generated from the offspring of CreERT2-Cxcl4L1/L1 mice after the ubiquitous
deletion of CXCL4 by tamoxifen. Mice double deficient for C5aR1 and CXCL4
(C5ar1−/−Cxcl4−/−) were bred in our own animal facility (on a C57BL/6 back-
ground). GFP-C5ar1fl/fl mice have been described previously30. Briefly, GFP-
C5aR1-knock-in mice were generated by gene targeting. (Ac)GFP and an internal
ribosomal entry site (IRES) were inserted adjacent to the coding exon of C5ar1.
Simultaneously, the AcGFP IRES C5ar1 cassette was flanked with two loxP sites.
We then crossed these mice with a Pf4-cre strain expressing Cre-recombinase
under control of the platelet- and megakaryocyte-specific promoter31 to generate
platelet-specific C5ar1-knockout mice.
For characterization of this new strain, platelets, leukocytes, and red blood cells
were counted using a Sysmex cytometer (Sysmex KX-21N, Görlitz, Germany).
Genotyping of floxed GFP-C5ar1fl/fl Pf4-cre mice. For genotyping, we used ear
biopsies. DNA was extracted from the tissue using a Qiagen Blood and Tissue DNA
Extraction Kit (Qiagen, Hilden, Germany), following the manufacturer’s instruc-
tions. For amplification of the different fragments, we used the DreamTaq PCR Kit
(Thermo Fisher Scientific, Waltham, MA, USA) and the following primers:
C5ar1flox_primer_01F: 5′-TAGAGTTGAGACTCAGAAAGACGG-3′, C5ar1flox_
primer_02R:5′-GTACACGAAGGATGGAATGGTG-3′, C5ar1flox_primer_03F:
5′-CTAGGCCACAGAATTGAAAGATCT-3′, and C5ar1flox_primer_04R: 5′-GT
AGGTGGAAATTCTAGCATCATCC-3′; GFP_primer_01F: 5′-TAGAGTTGAGA
CTCAGAAAGACGG-3′, GFP_primer_02R: 5′-GGGTGGACAGGTAGTGGTTA
TC-3′; Pf4-cre_primer_01F: 5′-CCCATACAGCACACCTTTTG-3′, Pf4-cre_
primer_02R: 5′-TGCACAGTCAGCAGGTT-3′, Pf4-cre_primer_03F: 5′-CAAATG
TTGCTTGTCTGGTG-3′, and Pf4-cre_primer_04R: 5′-GTCAGTCGAGTG-CAC
AGTTT-3′ (all from biomers.net, Ulm, Germany; see also Supplementary Data 1).
PCR was run under the following conditions: 95 °C for 3 min, followed by 35 cycles
at 95 °C for 30 s, 68 °C or 65 °C for 30 s, and 72 °C for 150 s, followed by 72 °C for
300 s. Then the samples were loaded onto a 1.5% TAE-agarose gel. The amplifi-
cation products were detected by ethidium bromide staining.
Mouse hindlimb ischemia model. We used a previously described protocol to
induce hindlimb ischemia98. Briefly, the femoral artery of mice aged 10–12 weeks
was ligated immediately distal to the branch point of the caudal femoral artery and
the epigastric artery. Tissue perfusion was assessed preoperatively, immediately
post‐ligation, and at 2, 4, 6, 8, 10, and 14 days after the surgical intervention, as
previously described99,100. Blood flow in the hindlimb was analyzed using an
infrared LDI (Moor Instruments, Axminster, UK) at 37 °C under medetomidine/
midazolam (0.5/5 mg/kg) anesthesia. For some experiments, platelet-depleting
serum (10 μl per dose in 200 μl phosphate-buffered saline (PBS), Accurate Che-
mical and Scientific, Westbury, USA) was applied principally as described
previously23,24 on days 1 and 5 by intraperitoneal (i.p.) injection. Successful platelet
depletion was monitored in the peripheral blood of mice taken retro-orbitally
(Supplementary Fig. 5).
For further experiments, we applied the C5aR1 antagonist PMX205 in the
hindlimb ischemia model. As suggested by a recent publication on the
pharmacokinetics of PMX205101, we applied the substance subcutaneously every
24 h at a dose of 1 mg/kg.
Data were analyzed with the Moor LDI image processing software (Moor
Instruments) and reported as the ratio of flow in the ischemic versus nonischemic
hindlimb. Furthermore, after 4, 7, or 14 days, some mice were sacrificed and
systemic perfusion with 15 ml PBS at 37 °C was performed to clear the vessels.
Then the gastrocnemius muscles of the ischemic and nonischemic limbs were
harvested, snap-frozen or perfused with 4% paraformaldehyde (PFA), and
processed for histological analysis.
Images of whole-muscle sections were acquired by tile scanning with a Zeiss
AxioObserver.Z1 microscope and Zen acquisition software. Vessels were stained by
IB4, and vessel density was assessed as the fraction of IB4-positive structures per
whole-muscle area. Arterial structures were visualized by staining for IB4 and
SMA. Pericytes were assessed by staining for NG2. Collateral artery diameter was
assessed by automatically measuring the perimeter of the five largest arterial
structures per whole-muscle section. Arteriolar density was assessed as the area
fraction of SMA-IB4 double-positive structures per whole-muscle area. Pericyte
density was assessed as the area fraction of NG2-positive structures per whole-
muscle area, and pericyte coverage was calculated as the spatial colocalization of
NG2 and IB4 within whole-muscle sections. All quantifications were performed
using the Image Pro Plus Software (Ver. 7.0, Media Cybernetics). A total of
10 sections, each 200 μm apart, were analyzed per muscle.
Sample preparation for microCT. For microCT analysis, 9 days after induction of
ischemia, mice were injected with 50 μl heparin (i.p.). After 10 min, the mice were
euthanized, the thorax was opened, and the aorta was exposed. A catheter was
carefully inserted into the descending aorta and manually fixed with sutures, and
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the liver incised several times to permit drainage of blood. Then mice were per-
fused with PBS (37 °C, 80 ml) containing heparin and nitroglycerin to remove the
blood. μAngiofil® (Fumedica AG, Muri, AG, Switzerland) was prepared according
to a previously published protocol102 and then injected through the catheter in the
aorta until leakage from the liver was observed. Thereafter, it was left to polymerize
for 1 h at room temperature (RT). Legs were collected and immersion-fixed in 2%
PFA–PBS for 48 h followed by fixation in 70% ethanol. For tomographic imaging,
samples were immersed in paraffin (3 h) before they were covered by a thin layer of
paraffin and let air-dry.
Image acquisition by microCT. For tomographic imaging, we shaped the samples
minimally with a scalpel, wrapped the samples in X-ray transparent melamine resin
foam (Basotect, SWILO GmbH, Sta. Maria, Switzerland) and mounted them in a
standard sample holder inside a Bruker SkyScan1172 high-resolution micro-
tomography machine (Bruker microCT, Kontich, Belgium).
The X-ray source was set to a voltage of 70 kV and a current of 142 μA, with a
0.5-mm Al filter in the beam path. For the relatively low-resolution scans we show
here, we recorded a set of 315 projections of 820 × 1224 pixels at every 0.6° over a
180° sample rotation. Every projection was exposed for 1410 ms, and three
projections were averaged to one to reduce image acquisition noise. To cover the
entire leg, we performed an oversize scan with three subscans stacked along the
long axis of the leg. This resulted in approximately 35 min of imaging time per
sample and an isometric voxel size of 21.6 μm in the final data sets.
MicroCT reconstruction and vessel visualization. The projection images were
then subsequently reconstructed into a 3D stack of 8 bit gray value PNG images
with NRecon (Bruker, Version: 1.7.4.2). After reconstruction, we visualized the legs
with MeVisLab (Version 3.1 (2018-06-26 Release), MeVis Medical Solutions AG,
Bremen, Germany). We extracted the bone with a gray value threshold-based
region growing algorithm with manually placed seed points inside the bone. The
vessels were extracted with a “Vesselness” filter, which is calculated as a function of
the Hessian matrix. Threshold-based segmentation of this Vesselness measure
provided the vessels for a visualization with the MeVis Path Tracer, which is a
completely refactored fork of the “ExposureRender” framework by Thomas
Kroes103. For quantitative analysis of the vascular network within the hindlimbs,
thresholding was performed. Then bones were filled by flooding and analysis was
limited to “small” vessels in order to exclude bones. By skeletonization, vessel
diameters could be measured at centerlines. A graphical representation of the
imaging data reconstruction and analysis algorithm is represented in Supplemen-
tary Fig. 8.
Quantitative real-time PCR (qPCR). Total RNA was isolated from the hindlimb
muscles of mice 1 week after the induction of hindlimb ischemia; total RNA was
also isolated from the nonischemic contralateral control hindlimb muscles. The
tissue was perfused with PBS and ground cryogenically, and RNA was isolated
using TriFast (peqgold, VWR, Radnor, PA, USA) followed by purification with the
RNeasy Mini Kit (Qiagen, Hilden, Germany) including DNase I treatment (Qia-
gen) according to the manufacturer’s instructions. The RNA was quantified using a
NanoDrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA),
and RNA quality was evaluated by an Agilent Bioanalyzer 2100 (Agilent Tech-
nologies, Santa Clara, CA, USA). To generate cDNA, equal amounts of total RNA
were converted into cDNA using the Transcriptor First Strand cDNA Synthesis Kit
(Roche Diagnostics, Rotkreuz, Switzerland). The cDNA samples were subjected to
qPCR amplification using the QuantiTect SYBR Green PCR Kit (Qiagen) and a
LightCycler 480 (Roche). The primers used were as follows: actin, 5′-
cgtgggccgccctaggcacca-3′ and 5′-ttggccttagggttcagggggg-3′; Gapdh, 5′-cccttcatt-
gacctccaactacaatggt-3′ and 5′-gaggggccatccacacgtcttctg-3′; CD42b, 5′-tggcttcatcc-
cacaacaag-3′ and 5′-tttctgaaggactggcacga-3′; CD41, 5′-tggcttcatcccacaacaag-3′ and
5′-tttctgaaggactggcacga-3′; and C5ar1 5′-tatagtcctgccctcgctcat-3′ and 5′-tcaccacttt-
gagcgtcttgg-3′ (see also Supplementary Data 1). The following PCR cycling para-
meters were used: 95 °C for 15 min; 50 cycles of 15 s at 94 °C, 30 s at 52 °C, and 30 s
at 72 °C.
Dissociation curve analysis was performed on all PCR products to ensure that
specific PCR products were generated. PCR was performed in triplicate for every
product, and the data were analyzed using the LightCycler software (v.1.5, Roche)
with the Ct advanced relative quantification function.
For the detection of CXCL4 mRNA in megakaryocytes, RNA was isolated as
described for hindlimb muscle tissue. Transcription into cDNA was performed
using Random hexamer primer mix (Carl Roth GmbH, Karlsruhe, Germany),
MMLV RT (Thermo Fisher Scientific), and RiboLock (Thermo Fisher Scientific).
Equal amounts of cDNA were applied for qPCR amplification using Luna
Universal qPCR Master Mix (New England Biolabs, Ipswich, MA) and 7900 HT
Real-Time PCR System (Applied Biosystems). The following primers were used:
cxcl4 5′-ttcagtggcaccctcttgac-3′ and 5′-atctccatcgctttcttcgg-3′; gapdh 5′-
gaccacagtccatgccatcac-3′ and 5′-ccgttcagctctgggatgac-3′. The following PCR cycling
parameters were used: 95 °C for 10 min, 40 cycles of 15 s at 95 °C and 60 s at 60 °C,
and finally 15 s at 95 °C, 15 s at 60 °C, and 15 s at 95 °C. The data were analyzed
using the Delta-Delta-CT-Method.
In vivo Matrigel plug assay. The in vivo Matrigel plug assay was performed as
previously described12 with some modifications. Two aliquots of Matrigel (0.5 ml,
Corning, Tewksbury, MA, USA) containing recombinant hirudin (22.4 U/ml,
Merck, Darmstadt, Germany) supplemented with bFGF (150 ng/ml, PeproTech,
Rocky Hill, NJ, USA) were subcutaneously injected into the mid-abdominal region
of mice, one aliquot on each side. Hirudin was used as an anticoagulant because the
classical anticoagulant heparin that is usually used in Matrigel plug assays has been
shown to inhibit complement activation104. Furthermore, heparin is known to
form complexes with CXCL459. In some experiments, Matrigel was supplemented
with freshly isolated murine platelets (108/ml Matrigel) from various knockout
mice, in addition to bFGF, as indicated in the figure legends. In rescue experiments,
the Matrigel injected into knockout animals was supplemented with WT or
knockout platelets. Other Matrigel experiments involved intravenous injection of a
blocking anti-CXCL4 antibody (10 μg/mouse, rat anti-mouse IgG2b, Clone 140910,
R&D, Minneapolis, MN, USA) or control IgG2b (BioLegend, San Diego, CA, USA)
as previously described36. Furthermore, in some experiments, Matrigel was sup-
plemented with the C5aR1 antagonist PMX53 (AcF[OPdChaWR], Tocris
Bioscience, R&D) or a control peptide (PMXcontrol; AcF[OPdChaAdR], Tocris) at
5 μg for each Matrigel plug (500 μl), which has been reported as a successful dose
for local injection, previously105.
After 7 days, mice were sacrificed, and the Matrigel plugs were fixed with 4%
PFA, processed for histology (frozen sections), and stained with hematoxylin and
eosin using standard staining protocols and reagents. Bright-field images were
obtained with a Nikon Optishot-2 microscope equipped with a ×2 plan-
apochromat (N.A. 0.08) objective lens and a digital sight DS-5M camera using the
Nikon NIS elements BR software (v.3.2, Nikon Instruments, Tokyo, Japan) for
image acquisition and analysis. For readout, the ratio of the vessel area to the
Matrigel plug area was calculated. Furthermore, immunofluorescent staining using
IB4 was performed to visualize plug neovascularization as described in
immunofluorescence microscopy studies.
Intravital microscopy and bleeding time. Bleeding time experiments were carried
out principally as described before24. Briefly, mice were anesthetized, and a 3-mm
segment of the tail tip was removed with a scalpel. Tail bleeding was monitored by
gentle absorption of the blood with filter paper at 20-s intervals without making
contact to the wound site. Intravital microscopy and induction of platelet thrombus
formation in vivo were carried out as described before106.
Human samples. For experiments with human material, written informed consent
was received from participants prior to inclusion in the study. The study was
approved by the institutional ethics committee (270/2011BO1) and complies with
the Declaration of Helsinki and the good clinical practice guidelines.
Flow cytometry. Most flow cytometry stainings were performed in citrated whole
blood, which was drawn from mice as described below. Blood was diluted 1:5 using
Tyrode’s solution (pH 7.4, supplemented with 1mM CaCl2 and 1mM MgCl2). In
some experiments, blood was stimulated with the following agonists for 10min at
37 °C: ADP (5, 20, 100 μM, Chrono-log Corporation, Havertown, PA, USA); CRP
(0.5, 2, 5 μg/ml; CambCol Laboratories, Cambridge, UK); C5a (2, 20, 200, 2000 ng/ml;
R&D). After stimulation, blood was diluted 1:5 once again to stop activation and
staining was performed at RT for 30min using the following antibodies: anti-mouse
CD88-APC (C5aR1, clone 20/70, Biolegend, #135808); rat anti-mouse Cd62P-FITC
(P-selectin, clone Wug.E9, Emfret Analytics, Eibelstadt, Germany, #D200); rat anti-
mouse JONA-PE (integrin aIIbß3(activ.form), clone JON/A, Emfret Analytics, #
D200); anti-mouse GPVI-FITC (Rat IgG2a, clone JAQ1, Emfret Analytics, #M011-1);
anti-mouse CD61-PE594 (Biolegend, #104321v); anti-mouse CD40L (IgG MR1,
Biolegend, # 106512); anti-mouse CD45-BV605 (Biolegend, #103139); anti-mouse
CD41-PacificBlue (Biolegend, #133932); anti-mouse CD63-PECy5.5 (clone NKI/C3,
Novus Biologicals, Littleton, CO, USA, #NBP2-34694PECY55); anti-mouse GPII-
bIIIa-FITC (anti-integrin αIIbβIII, clone Leo.F2, Emfret Analytics, #M025-1); anti-
mouse CD49e-PE, (Biolegend, #103805); anti-mouse CD42b-PE (anti-GPIbα Rat
IgG2b, clone Xia.G5, Emfret Analytics, #M040-2); anti-mouse integrin α5 chain-FITC
(clone Tap.A12, Emfret Analytics, #M080-1); anti-mouse GPIX-FITC (CD42a Rat
IgG1, clone Xia.B4, Emfret Analytics, #M051-1); anti-mouse CLEC-2-PE (CLEC1B,
clone 17D9, Biolegend, # 146103). After staining, cells were fixed using freshly pre-
pared 4% PFA solution and diluted using FACS buffer (PBS, 0.5% bovine serum
albumin (BSA), 0.1% Na-Azide). Gating was performed by CD41 and CD45 as well as
FSC and SSC at a logarithmic scale. Platelets were defined as CD45−CD41+ and
differentiated from debris using FSC and SSC (see also Supplementary Fig. 26).
For the detection of C5aR2 expression in platelets, platelets were isolated from
tdTomato-C5aR2 reporter mice and controls. The gating antibody CD41-
PacificBlue was already added to the whole blood during platelet isolation.
Acquisition was performed without prior fixation.
For detection of calcium signaling in platelets using flow cytometry, we used a
previously published protocol107. Briefly, platelets were isolated using activation
inhibitors (as described below), washed, quantified, and loaded with calcium-
sensitive dyes fluo-4 and fura-red as well as a CD41-PacificBlue as gating antibody
for 20 min at 37 °C. Platelets were then resuspended at a concentration of 104/μl in
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a buffer containing ionomycin (3 μg/ml), nigericin (2 μg/ml), and CCCP (10 μM).
After addition of calcium, level was acquired for 30 s, then the stimulant was added.
In another experiment, platelets isolated from Matrigels were stimulated with
ADP (0.1 mM, Chrono-log Corporation) for 30 min at 37 °C and stained with
CD62p-FITC (rat anti-mouse P-selectin, clone Wug. E9) or an appropriate isotype
control (rat IgG1, both from Emfret Analytics) for the assessment of platelet
activation.
Most flow cytometry experiments were performed using a Beckman Coulter
Cytoflex S 4-laser cytometer (Beckman Coulter, Krefeld, Germany) immediately
after sample preparation and staining. Unless otherwise stated, specific mAb
binding was expressed as the mean fluorescence intensity (MFI) of 25,000 events in
the target gate, and data were analyzed using the CytExpert software (v.2.4,
Beckman Coulter).
For the characterization of C5aR1 expression on immune cells in Pf4-cre− GFP-
C5ar1fl/fl and Pf4-cre+ GFP-C5ar1fl/fl mice, 200 μl of citrate whole blood were used
per sample. Ten microliters of FcR Block (Miltenyi Biotec) was added to each
sample followed by 50 μl of antibody dilution of pre-titrated antibodies. Antibodies
were F4/80-BV785, CD11b-BV605, and CD14-APC (all BioLegend) and CD45 PE-
Cy5.5 (eBioscience) and incubated for 20 min in the dark at RT. Samples were
treated with ammonium chloride red blood cell lysis and washed with PBS. After
spinning down again, cells were stained with Zombie NIR (dead cell stain,
BioLegend, 1:600) for 15 min in the dark. Cells were washed and resuspended in
FACS-Buffer for analysis. Analysis was performed on a LSRFortessa flow cytometer
(BD Bioscience) with a violet (402 nm), blue (488 nm), yellow/green (561 nm), and
red (640 nm) laser. Specific mAb binding was expressed as the MFI, and data were
analyzed using the FloJo software (v.10, Tree Star, Ashland, OR, USA).
ATP release. Aggregation of platelets was estimated with light transmission aggre-
gometry using a lumiaggregometer Model 700 (ChronoLog). Washed murine platelets
were adjusted to a concentration of 250 × 103 platelets per μl in Tyrode buffer pH 7.4
and were preincubated with PBS or 20 ng/ml C5a for 10min. After adjusting the
measurement according to the manufacturer’s protocol, platelets were activated with
0.25 μg/ml CRP or with 2.5mU/ml thrombin for 10min at 37 °C and a stirring speed
of 1000 rpm. Analysis was performed using the aggrolink8 software (ChronoLog).
Aggregometry. Aggregation of platelets was estimated with light transmission
aggregometry using a lumiaggregometer Model 700 (ChronoLog). Washed murine
platelets were adjusted to a concentration of 250 × 103 platelets per μl in Tyrode
buffer pH 7.4 and were preincubated with PBS or 20 ng/ml C5a for 10 min. After
adjusting the measurement according to the manufacturer’s protocol, platelets were
activated with 0.25 μg/ml CRP, with 2.5 mU/ml thrombin, or further agonists for
10 min at 37 °C and a stirring speed of 1000 rpm. Analysis was performed using the
aggrolink8 software (ChronoLog). For human samples, platelet-rich plasma (PRP)
was generated as described above and used for aggregometry with platelet-poor
plasma as a control; stimulation was performed using ADP and CRP as well as C5a
at defined concentrations.
Immunofluorescence microscopic studies. From ischemic murine hindlimb
muscle tissue, 8-μm-thick sections of the gastrocnemius muscle were processed for
immunofluorescence staining. Matrigel sections were processed accordingly. For
PFA-perfused tissue, we performed antibody retrieval as described previously108.
Briefly, we rehydrated tissue in PBS and then heated the tissue to 70 °C in 1 mM
EDTA (pH 8.00) three times. Snap-frozen tissue was fixed for 10 min in ice-cold
acetone and blocked with 10% goat or donkey serum and 1% BSA for 30 min at RT.
Subsequently, the sections were incubated with primary antibody in 1% blocking
serum containing CaCl2 and 0.2% Tween 20 overnight at 4 °C. Furthermore, when
tertiary amplification was used, a biotin blocking kit (Thermo Fisher) was applied.
As primary antibodies, we used Isolectin GS-IB4 Alexa Fluor 594 (Invitrogen,
Carlsbad, CA, USA, 1:100), rat anti-mouse anti-C3 antibody (clone 11H9, ab11862,
Abcam, Milton, UK, 1:20), α-actin antibody (clone1A4, sc-32251, Santa Cruz
Biotechnology, Dallas, TX, USA, 1:20), rabbit anti-mouse anti-NG2 chondroitin sulfate
proteoglycan antibody (Merck, AB5320, 1:20), rabbit polyclonal anti-CXCL4 antibody
(PAA172Mu01, Cloud Clone Corp., Houston, TX, USA, 1:20), goat anti-mouse C5aR1
antibody (CD88, Santa Cruz, clone P14, sc-3124, 1:200), and rat anti-mouse GPIb
antibody (CD42b, clone POP-B, Emfret Analytics, 1:100). For visualization or
secondary amplification, we incubated samples with donkey anti-rat highly cross-
adsorbed IgG coupled with biotin (Thermo Fisher, 1:500), donkey anti-rabbit highly
cross-adsorbed IgG Alexa Fluor 647 (Thermo Fisher, 1:100), donkey anti-goat Alexa
Fluor 488 antibody (Invitrogen, 1:200), goat anti-rat Alexa Fluor 568 antibody
(Invitrogen, 1:1000), goat anti-rat cross-adsorbed IgG Alexa Fluor 488 (Thermo Fisher,
1:500), goat anti-rabbit Alexa Fluor 488 antibody (Invitrogen, 1:500), and goat anti-
rabbit IgG coupled with biotin (ab6720, Abcam, 1:200). If required, we performed
tertiary amplification using Streptavidin Alexa 546 (Thermo Fisher, 1:200) in a buffer
containing 100mM Tris-HCl, pH 7.5, 150mM NaCl, 0.3% Triton X-100, and 1%
BSA. Finally, the sections were probed with DAPI (Sigma Aldrich, Taufkirchen,
Germany, 1:3000) to visualize the nuclei.
The stained sections were mounted on glass slides, and image acquisition of
muscle sections was performed as described earlier. Higher-magnification images
were taken using a Zeiss LSM 800 confocal laser scanning microscope with the
Zeiss ZEN 2.3 (blue edition) software. Subsequent image analysis was performed
with Image Pro Plus (Ver. 7.0).
For single-cell staining, we blocked samples with 10% donkey serum and used
the following primary antibodies: mouse monoclonal P-selectin antibody (CTB201,
sc-8419, Santa Cruz, 1:50), rat anti-mouse CD88 antibody (C5aR1, BioLegend,
#135815 1:60), and rabbit polyclonal CXCL4 antibody (PAA172Mu01, Cloud
Clone Corporation, Houston, TX, USA, 1:12). For visualization, the following
secondary antibodies were used: donkey anti-mouse preadsorbed IgG Alexa Fluor
488 (ab150109, Abcam, 1:200), donkey anti-rabbit highly cross-adsorbed IgG Alexa
Fluor 647 (Thermo Fisher, 1:100), and donkey anti-rat preadsorbed IgG Alexa
Fluor 568 (ab175475, Abcam, 1:200). Images were acquired using a Zeiss LSM 800
confocal laser scanning microscope with Zeiss ZEN 2.3 (blue edition) software or
an Olympus Fluoview 1000. Subsequent image analysis was performed with Image
Pro Plus (Ver. 7.0). For analysis of single platelet granule composition, we took
snapshots of single platelets from confocal immunofluorescence images, and
granules were differentiated by distinct regions of interest in a fluorescence scatter
plot using Image Pro Plus (Supplementary Fig. 10).
For the characterization of platelet abundance in ischemic hindlimb tissue,
CD42b-positive signals were quantified according to size characteristics in an
automated fashion as single platelets or microthrombi using Image Pro Plus
(Ver. 7.0).
For the staining of megakaryocytes, we blocked samples with 5% donkey serum
and used the following primary antibodies: purified rat anti-mouse CD62P (BD
Pharmingen, San Jose, CA, USA, 1:50) and rabbit polyclonal CXCL4 antibody
(PAA172Mu01, Cloud Clone Corporation, 1:12). The following secondary
antibodies were used: Donkey F(ab’)2 anti-rat IgG (H+ L)-Alexa Fluor 647 (#712-
606-153, Dianova, Hamburg, Germany, 1:250) and Donkey anti-rabbit IgG (H+
L)-Cy3 (#711-165-152, Dianova, 1:250). Cell nuclei were stained using YOPRO
(green signal). Images were acquired using a Zeiss LSM 800 confocal laser scanning
microscope with Zeiss ZEN 2.3 software, and analysis was performed by the Image
Pro Plus software as illustrated in Supplementary Fig. 10.
Isolation of human and murine platelets and generation of platelet releasate.
Human and mouse washed platelets were isolated from human or mouse blood as
previously described109,110. Briefly, human venous blood was donated by healthy
volunteers. Blood was drawn from the antecubital vein into acid–citrate–dextrose
(ACD) buffer and centrifuged at 430 × g for 20 min. PRP was removed and added
to HEPES-buffered Tyrode’s solution (2.5 mM HEPES, 150 mM NaCl, 1 mM KCl,
2.5 mM NaHCO3, 0.36 mM NaH2PO4, 5.5 mM glucose, and 1 mg/ml BSA, pH 6.5)
and subsequently centrifuged at 900 × g for 10 min. The resulting platelet pellet was
resuspended in HEPES-buffered Tyrode’s solution (pH 7.4, supplemented with 1
mM CaCl2 and 1 mM MgCl2). Platelets were then preincubated with a C5aR1
antagonist (10 μM; PMX53, AcF[OPdChaWR], Tocris) for 30 min at 37 °C or
control peptide (AcF[OPdChaAdR]) as previously described111. Subsequently,
platelets were coincubated with endothelial cells to assess the impact of platelet
C5aR1 blockade on endothelial tube formation in vitro.
To isolate murine platelets, blood was drawn from the heart or the retro-orbital
plexus, collected in ACD buffer, and centrifuged at 120 × g for 20 min. PRP was
resuspended in HEPES-buffered Tyrode’s solution (pH 6.5) and then centrifuged at
2600 × g for 10 min. The platelet pellet was carefully resuspended in HEPES-
buffered Tyrode’s solution (pH 7.4). HEPES-buffered Tyrode’s solution was
supplemented with 1 mM CaCl2 and 1 mM MgCl2. The platelet content was
quantified using a Sysmex cytometer (Sysmex KX-21N, Görlitz, Germany) and was
adjusted to the required concentration. Subsequently, either the platelets were
stimulated, the supernatant was collected or lysed, and the platelets were used for
single-cell staining or the platelets were used at specific concentrations for
coincubation with endothelial cells, resuspended in Matrigel for injection into mice,
or used in flow cytometric analyses. For some experiments, platelet isolation was
performed using activation inhibitors prostacyclin (0.5 μM, sigma Aldrich) and
apyrase (0.02 U/mL, Sigma Aldrich).
As agonists for stimulation of murine as well as human platelets, we used CRP
(CambCol) at specified concentrations, ADP (Chrono-log Corporation), C5a
(R&D), thrombin (Roche), TRAP-6 (TRAP, Diasys, Holzheim, Germany),
thromboxane A2 (U46619, TxA2, R&D), phorbol 12-myristate 13-acetate (Abcam)
at 100 ng/ml (approximately 160 nM), and the C5aR2 agonist P32 (used at 1 μM),
which has been described previously112. For some experiment, platelets were
preincubated with the C5aR1 antagonist PMX205 (used at 15 μM for 30 min at
37 °C, Tocris) or control peptide. Subsequently, platelets were stimulated with C5a.
If not otherwise stated, stimulation with C5a (R&D) was performed at a
concentration of 20 nM for 10 min at 37 °C as previously described for other cell
types12. Following C5a stimulation, the supernatant was collected by centrifugation
at 14,000 × g at 4 °C and analyzed or used to stimulate endothelial cells. The pellet
was lysed using RIPA buffer supplemented with protease/phosphatase inhibitor
(Halt, Thermo Fisher) and analyzed by western blotting.
For single platelet staining, 5 μM ADP was used along with C5a for 5 min at RT
or in other experiments for 10 min at 37 °C. After stimulation, platelets were fixed
using PFA. Resting, C5a-stimulated, or ADP-stimulated fixed platelets were
immobilized on poly-L-lysine-coated coverslips and stained using the antibodies
and staining conditions specified above.
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For lysate preparation, 100 × 106 platelets were lysed using RIPA buffer and
protease inhibitor (Halt, Thermo Fisher) in a volume of 100 μl. In other
experiments, the supernatant of C5a-treated platelets was immunodepleted of
CXCL4 following a protocol that was previously described12. Briefly, supernatants
were incubated overnight at 4 °C with 100 μg/ml anti-CXCL4 antibody (rat IgG2b,
MAB 595, R&D) or IgG2b control (BD Biosciences, San Jose, CA, USA). Then
washed protein G-coupled Sepharose beads (4 Fast Flow, GE Healthcare, Little
Chalfont, UK) were added to the supernatant and incubated for 2 h at 4 °C, and
then immune complexes were removed by centrifugation at 14,000 × g for 5 min.
The resulting CXCL4-depleted supernatant was subsequently incubated with
endothelial cells.
Enzyme-linked immunosorbent assay. Platelet releasates were analyzed by ELISA
using a mouse PF4/CXCL4 Quantikine ELISA Kit (R&D), a membrane-based
antibody array (Proteome Profiler Mouse Angiogenesis Array Kit, ARY015, R&D),
a Serotonin ELISA Kit (BA E-8900, LDN, Nordhorn, Germany), a Hexosaminidase
B (HEXb) ELISA Kit (SEA637Mu, Cloud Clone Corporation), a Mouse VEGF
ELISA Kit (ab209882, Abcam), a Thrombospondin 1 ELISA Kit (THBS1,
ABIN6574175, Antibodies-Online, Aachen, Germany), an endostatin COL18A1/ES
ELISA Kit (Mouse collagen type XVIII α 1 Endostatin ELISA Kit, MBS701673,
MyBioSource.com, San Diego, USA), and a TIMP-1 ELISA Kit (Mouse TIMP-1
Quantikine ELISA, MTM100, R&D). For human samples, we used a human
CXCL4/PF4 Quantikine ELISA Kit (R&D), a human thrombospondin-1 Quanti-
kine ELISA Kit (R&D), a human PDGF BB ELISA Kit (ab100624, Abcam), and a
human Endostatin ELISA Kit (RayBiotech, Peachtree Corners, GA, USA).
For ex vivo analysis, tissue homogenates were prepared from ischemic and
nonischemic gastrocnemius muscles by cryo-grinding the tissue with a mortar and
pestle after exposure to liquid nitrogen. The pulverized tissue was then resuspended
in PBS supplemented with protease inhibitor (Roche) and subjected to sonication
twice at maximum intensity while keeping the sample on ice. Debris was removed
by centrifugation at 5000 × g for 5 min, and the supernatant was harvested. Samples
were adjusted to equal protein concentrations and probed for CXCL4 content using
another ELISA Kit (SEA172Mu, Cloud Clone Corp.) according to the
manufacturer’s instructions.
Western blot analysis. Platelet lysates were separated by sodium dodecyl sulfate
(SDS)-polyacrylamide gel electrophoresis using a 12% gel and subjected to western
blot. Whole-protein detection was performed, and nitrocellulose membranes were
incubated with primary rat IgG2b CD88-specific antibody (10/92, Hycult Biotech,
Uden, Netherlands). We used goat anti-rat 800 CW (LI-COR, Bad Homburg,
Germany) as a secondary antibody and REVERT total protein stain (LI-COR) for
normalization. Membranes were scanned with the Odyssey Infrared Imaging
System (LI-COR) and analyzed.
For other experiments, platelets were lysed in RIPA buffer (150 mM NaCl, 50
mM TRIS, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton-X 100, and complete
protease inhibitor cocktail (PI)) and boiled in SDS sample buffer for 10 min at 95 °
C. Next, samples were separated by SDS-polyacrylamide gel electrophoresis and
transferred to polyvinylidene difluoride membranes using the iBlot2 system
(Thermo Fisher). Transfer success and total protein content was quantified by
Ponceau staining. Membranes were then blocked with 5% skim milk or 5% BSA
(for the detection of phosphorylated antigens) in Tris-buffered saline 0.05%
Tween-20 and incubated with the following primary antibodies: anti-mouse C3aR
(Santa Cruz Biotechnologies; clone D12; 2 μg/ml); thrombospondin 1 (rabbit
polyclonal Anti-Thrombospondin-1 Antibody, Proteintech, Chicago, IL, USA, #1
18304-1-AP, 1:2000); phospho PLCγ2 (Tyr1217, Cell Signaling Technology,
#3871S, 1:1000), total PLCγ2 (Cell Signaling Technology, Danvers, USA, #3872S,
1:1000); phospho PKA (PKA α/β/γ catalytic subunit phospho T197, Abcam,
#ab75991, 1:3000), total PKA (α/β catalytic subunits, Abcam, #ab216572, 1:500);
phospho Akt (Ser473, Cell Signaling Technology, #9271S, 1:1000), total Akt
(Rabbit monoclonal Akt pan C67E7, Cell Signaling Technology, # 4691S, 1:1000);
phospho PI3K (Phospho PI3 Kinase p85 Tyr458/p55 Tyr199, Cell Signaling
Technology, #4228S, 1:1000), total PI3K (rabbit monoclonal PI3 Kinase p85 19H8,
Cell Signaling Technology, #4257S, 1:1000); phospho GSK-3β (Ser9, Cell Signaling
Technology, #9336S, 1:1000), total GSK-3β (rabbit monoclonal anti GSK-3β
27C10, Cell Signaling Technology, #9315S, 1:1000); phospho p44/42 MAPK (Erk1/
2 Thr202/Tyr204, Cell Signaling Technology, #9101S, 1:1000), total p44/42 MAPK
(Erk1/2, Cell Signaling Technology, #9102S, 1:1000); phospho PLCβ3 (Ser537, Cell
Signaling Technology, #29021S, 1:1000), total PLCβ3 (rabbit monoclonal PLCβ3
D9D6S, Cell Signaling Technology, #14247, 1:1000); phospho PKC (Ser) substrate
(Cell Signaling Technology, #2261S, 1:1000), total PKCα (Cell Signaling
Technology, #2056S, 1:1000).
As loading controls, we used anti-α-Tubulin (Sigma Aldrich, #T5168, diluted
1:4000) and anti-β-actin (Abcam, #8226, 1:1000) and incubated at 4 °C overnight.
As secondary horseradish peroxidase (HRP)-conjugated antibodies, we used HRP-
conjugated goat-anti-rabbit IgG H&L (Abcam, ab205718) as well as HRP-
conjugated goat-anti-mouse IgG H&L (Abcam, ab205719). Antibodies were
incubated for 1 h at RT, and membranes were washed thrice with Tris-buffered
saline 0.05% Tween-20. Membranes were developed using the LS ECL PRIME
WESTERN BLOTTING SYSTEM (GE Healthcare) and scanned with a
Chemiluminescence Imaging System (Biorad, Feldkirchen, Germany) and
analyzed.
Rap1 activation and pulldown assay. For detection and pulldown of activated
Rap1 (GTP-Rap1), a commercially available kit (affinity precipitation assay) was
used and performed according to the manufacturer’s recommendations (Rap1
Activation Assay Kit, product number 17-321, EMD Millipore, USA)113.
Isolation of primary MLECs. Primary MLECs were isolated according to a pre-
viously published protocol114. Briefly, lungs were removed from C57Bl/6 or Cxcr3
−/− mice, washed in Dulbecco’s modified Eagle’s medium (DMEM, Gibco, Thermo
Fisher) containing 10% fetal bovine serum (FBS, Gibco, Thermo Fisher)+
penicillin–streptomycin (P/S, Thermo Fisher), and minced into 1–2 mm³ pieces.
The tissue was digested with collagenase type I (2 mg/ml, Gibco, Thermo Fisher) in
DMEM containing 0.1% BSA for 3–4 h at 37 °C with occasional shaking, and the
resulting suspension was passed through a 70-μm cell strainer. After pelleting, the
cells were resuspended in DMEM/F12 (Gibco, Thermo Fisher) containing 20%
FBS, P/S, and 100 μg/ml endothelial cell growth supplement (ECGS, Corning) and
seeded in T25 culture flasks coated with 0.4% gelatin (Sigma-Aldrich). After
incubation overnight, floating and loosely adherent cells were removed by washing
with PBS, and new growth medium+ ECGS was added. Cells were grown until
near confluence, with fresh growth medium+ ECGS added daily. Anti-rat Dyna-
beads (Invitrogen) were preincubated with rat anti-mouse CD102 antibodies
(Clone 3C4, BD) overnight in PBS containing 0.1% BSA and 2mM EDTA and
washed twice with DMEM containing 0.1% BSA. The beads were added to cell
culture flasks containing DMEM with 0.1% BSA and incubated for 10 min. Flasks
were then washed with PBS to remove unbound Dynabeads. After trypsinization,
bead-bound cells were isolated by washing 4× with DMEM 0.1% BSA on a magnet
to remove bead-free cells and then seeded into fresh T25 culture flasks coated with
0.4% gelatin. A second purification step was performed when the cells were con-
fluent, and the cells were then transferred to T75 flasks and harvested when near
confluence. Cell purity was verified by flow cytometric analysis for the expression
of CD102, CD31, and CD144 (Supplementary Fig. 2). All endothelial cell assays
using MLECs were performed within 2 weeks of the flow cytometric quality
control. Additionally, the murine endothelial cell line MHEC-5T115 was used and
HUVECs were purchased from PromoCell (Heidelberg, Germany) and cultured in
DMEM containing 10% FBS or Endothelial Cell Growth Medium (PromoCell).
HUVECs were generally used at low passages and grown on culture dishes pre-
coated with 0.2% gelatin (Sigma-Aldrich).
Platelet adhesion assay to endothelial cells and fibrinogen. Platelet adhesion to
endothelial cells was determined by quantifying the number of platelets per
endothelial cell area in a static adhesion assay. Briefly, MHEC-5T (150,000/well)
were plated onto gelatin-coated coverslips in a 24-well-plate and incubated for 14 h
in full medium or 10 h in full medium followed by 6 h under hypoxic conditions
(1% oxygen) in a low-glucose DMEM (Gibco). Isolated platelets (5 million/well)
were labeled using CD41 antibody (X488, Emfret Analytics) and incubated with the
endothelial monolayer for 30 min at 37 °C. Endothelial cells were washed twice
with PBS, fixed (1% PFA), and stained with DAPI. Finally, coverslips were placed
on slides and imaged using a digital microscope (BZ-9000, Keyence, Osaka, Japan).
Images were merged by the BZ-Analyzer software; platelet count was normalized
for endothelial area, both were quantified by ImageJ and Image Pro Plus 7.
For the assessment of static adhesion to fibrinogen, wells of a 96-well plates
were coated with fibrinogen (#341576, Merck Millipore) at 2 mg/ml at 4 °C
overnight. Murine WT or C5ar1−/− platelets were isolated as described and
stimulated with ADP (10 μM) and C5a (20 ng/ml) or vehicle control. The 96-well
plate was washed with prewarmed 0.9% NaCl and platelets (1 × 106/well) were
added to the wells and left to adhere for 1 h at RT. Plates were washed twice with
0.9% NaCl, and pictures were taken with a Visiscope inverted microscope (IT404).
A particle analysis was performed using the ImageJ software.
Cell proliferation assay, scratched wound assay, tube-formation assay, and
spheroid tube-formation assay. Endothelial cell proliferation was determined by
measuring the total number of adherent cells at different time points. Briefly,
MHEC-5T (5 × 104 cells/well) or MLECs (3 × 104 cells/well) were plated onto 96-
well plates and incubated for 6, 18, or 25 h in full medium; washed platelets were
resuspended in medium (5 × 106 cells/well) or vehicle control. Then the cells were
washed once with PBS and quantified. In some experiments, cell proliferation was
also assessed using a BrdU-ELISA Kit (Roche) according to the manufacturer’s
instructions. Readouts were taken after 18 h.
A scratched wound assay was performed as previously described110. Briefly,
MHEC-5T (2 × 105 cells/well) or MLECs (1 × 105 cells/well) were plated onto 24-
well plates and incubated for 24 h. Subsequently, the confluent cell monolayer was
wounded with a plastic pipette tip, generating a 1-mm-wide gap. Cells were then
incubated with washed platelets resuspended in medium (2 × 107 cells/well) or
vehicle control. In other experiments, cells were coincubated with the supernatant
of platelets generated as described earlier. As a measure of endothelial migration,
the area repopulated with MHEC-5T or MLECs after 16 or 28 h was quantified by
phase-contrast microscopy.
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For the in vitro tube-formation assay, MHEC-5T, HUVECs, or MLECs (3 × 104
cells/well) were plated onto Matrigel-coated 48-well tissue culture plates in
endothelial culture medium containing 1% FBS or on ibidi slides (ibidi, Planegg,
Germany) with medium containing 2% FBS. Cells were coincubated with washed
platelets (2 × 107 cells/well), vehicle control, or platelet supernatant. After 6.5, 12,
or 24 h, depending on the cell type, tube formation was imaged by phase-contrast
microscopy. Furthermore, preincubation of platelets with antagonists, such as
PMX53 (30 min at 37 °C, Tocris), was performed as described in the figure legends.
Using Axiovision software (v.3.2, Zeiss), the total tube length in multiple high-
power fields per well was assessed and quantified as the average total tube length
per well.
For the spheroid tube-formation assay, endothelial cell spheroids of defined cell
numbers were generated as previously described116. In brief, HUVECs were
suspended in culture medium containing 0.2% (wt/vol) carboxymethylcellulose
(Sigma-Aldrich) and seeded in round-bottom 96-well plates to form a single
spheroid per well (400 cells/spheroid). The spheroids were then embedded into rat
collagen I (BD), and the spheroid-containing collagen was rapidly transferred into
warm 24-well plates and allowed to polymerize for 30 min. Then 100 μl of
endothelial cell medium supplemented with platelet supernatant or vehicle control
was added to the wells. After 24 h, pictures were acquired using an Axiovert 100
microscope and a Plan-NEOFLUAR 10x objective. In vitro capillary sprouting was
quantified by measuring the cumulative length of sprouts per spheroid using the
Axiovision software. The mean cumulative sprout length per spheroid was
calculated after the evaluation of 10–15 spheroids/condition.
Embryonic hindbrain angiogenesis model. At day E11.5, the hindbrains of
murine WT and C5ar1−/− fetuses were successfully prepared, isolated, and stained
as whole mounts using a previously published protocol117. Briefly, isolated hind-
brains were fixed in 4% PFA for 2 h at RT and washed three times. Afterwards, they
were blocked using 0.1% Triton-X (Sigma-Aldrich) and 10% normal donkey serum
(Sigma-Aldrich) in PBS at 4 °C overnight and then incubated with Alexa-488-
conjugated Griffonia simplicifolia IB4 (1:200, Thermo Fisher) for 3 h at RT. The
ventricular plexus was analyzed using a Zeiss LSM5 EXCITER confocal laser
scanning microscope (Zeiss) with a ×10 objective. 3D confocal images were
reconstructed with ImageJ (NIH). Analysis of the vascular networks was performed
using a previously described method118 and AngioTool software (National Cancer
Center, Rockville, MD, USA) as recently described119.
Data presentation and statistics. The results are expressed as the mean ± SEM.
All statistical analyses were performed using GraphPad Prism 9. Comparisons
between two groups were performed using Student’s t test. Comparisons between
more than two groups were conducted using analysis of variance (ANOVA), and
comparisons between two groups with several time points were performed using
two-way ANOVA. Bonferroni’s post hoc test was performed for all ANOVA
analyses. p < 0.05 was considered statistically significant.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All relevant data are available upon request from the corresponding author. Source data
are provided with this paper.
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